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A physiologically-based toxicokinetic and toxicodynamic (PBTK/TD) model was
developed, from the open literature, to predict the toxicokinetic disposition and
toxicodynamic response (acetylcholinesterase inhibition) of a ternary organophosphorus
(OP) insecticide mixture: chlorpyrifos (CP), methyl parathion (MP) and parathion (P). In
vivo studies were conducted in adult male Sprague-Dawley rats, orally administered one
of two CP/MP/P mixtures (2.5, 0.5, 0.5 mg/kg or 5, 1, 1 mg/kg) with selected tissues
(blood, brain, diaphragm, liver, lung and skeletal muscle) collected at 30min, 4, 12 and
24hr postdosing. Low dosages were studied so the mixture did not result in significant
disruption of cardiovascular function nor invalidate the model’s underlying general
physiological assumptions. The data were used to validate the model. CP and its
metabolites (CP-oxon, 3,5,6-trichloro-2-pyridinol (TCP)), as well as MP, P and 4nitrophenol, were quantified in the tissues of interest. Peak concentrations of CP were
attained by 4hr in all tissues with the exception of the liver, whose peak occurred at

30min; MP, 30min in all tissues; P, 12hr in all tissues with the exception of the liver,
30min. This was supported by the model simulations. MP, P, and their respective oxons
were below limits of quantitation for the lower dosage. No toxicokinetic interactions
were observed in the present study. Cholinesterase inhibition in the tissues ranged from
11- 37% for the lower dosage, and 29-93% for the higher dosage group; with few
exceptions, inhibition was generally additive and was also supported by the model
simulations. This study demonstrates the utility of using previously developed individual
PBTK/TD models and in vitro/in vivo data from the open literature to construct reliable
mixture PBTK/TD models.

Key words: PBPK/PD Model; PBTK/TD Model; Mixtures; Organophosphorus
Insecticides; Esterase Inhibition.
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CHAPTER I
GENERAL INTRODUCTION

Exposure to chemicals in the environment, such as organophosphorus (OP)
insecticides, is rarely limited to a single chemical; they commonly coexist as
mixtures. Multi-chemical exposure is the rule rather than the exception in both
occupational and non-occupational environments. Individuals are likely to be exposed
to a wide range of OP insecticides, from many different sources, in variable
concentrations and routes of exposure. There are numerous public health concerns
regarding chemical mixtures; however, regulatory limit values are generally set for
single compounds. Research approaches and needs in this area have been well
described (Teuschler et al., 2002). To protect human health, insight is needed into the
combined action of chemicals, particularly OP insecticides.
We are potentially exposed to many different OP insecticides on a daily basis,
albeit at very low levels, in food residues, drinking water, homes and schools. In a
study by Simcox et al. (1995), azinphos-methyl, chlorpyrifos, parathion, and phosmet
were found in 62% of dust samples collected from the homes of agricultural workers,
demonstrating the potential for both occupational and non-occupational exposure to
insecticide mixtures. Consequently, it is imperative that multiple chemical effects and
interactions be considered in the risk assessment process. The mixture toxicity
1

problem has long challenged both toxicologists and regulators. As Haddad et al.
(1999) has articulated, the mechanism that generates the toxic response and is a prime
determinant of the putative human health risk cannot be examined sufficiently by
only studying the individual components of the mixture. Approaching the mixture
quandary with conventional toxicological studies is futile, due to the immense
number of possible mixture combinations. The utilization of physiologically-based
toxicokinetic/toxicodynamic (PBTK/TD) modeling is needed, as described in the
present study, to address the data gaps in the risk assessment process.
The value of PBTK/TD modeling is its potential predictive power, i.e., tissue
dosimetry at the toxico/pharmacokinetic and toxico/pharmacodynamic levels,
minimization of animal use, amenability to cross-species scaling, and simulation of
exposure scenarios that cannot be tested otherwise. Although PBTK/TD models have
been developed for a variety of single chemicals, far fewer PBTK/TD models have
been developed for chemical mixtures; the present study helps to fill that deficiency.
One of the best-known examples of PBTK model development for concurrent
exposure to a binary mixture of chemicals is that of trichloroethylene (TCE) and 1, 1dichloroethylene (DCE). In this work, Andersen et al. (1987) linked the two single
chemical models by the mass-balance equation for the liver and produced generalized
liver mass-balanced equations that could be used to test for competitive, noncompetitive, and uncompetitive inhibition by manipulating the values of various
terms within the equations. Somewhat more recently, Tardif et al. (1995) developed a
PBTK model for the interaction of toluene and xylene that was expanded into a
2

human PBTK model for toluene and mixed xylenes. In this study, individual PBTK
models were developed for toluene and xylenes in adult male rats, then the two
models were linked through a metabolism term in the liver. Subsequently, similar
modeling approaches have been employed by El-Masri et al. (2004) and Timchalk et
al. (2005) for binary OP mixture PBTK/TD models (chlorpyrifos/parathion and
chlorpyrifos/diazinon, respectively).
Unquestionably, pesticides have greatly benefited our society by protecting
our food supply, controlling harmful pests, and improving quality of life.
Nevertheless, the widespread use of pesticides is not without risk for our environment
and our health. OP insecticides are extensively used because of their efficacy against
insect pests, rapid degradation, and lack of cross resistance in many insects as
compared to the earlier organochlorine insecticides. The development of OP
compounds as insecticides emerged through nerve gas research conducted in 1937 by
Gerhard Schrader, Bayer Chemical Company, Germany. Schrader recognized the
insecticidal significance of OP compounds and in 1944, methyl parathion and
parathion were introduced as replacements for nicotine in aphid control.
Subsequently, the number of OP insecticides rapidly grew during the 1950’s and 60’s
in the United States. Presently, OP compounds are the largest family of insecticides.
Although the introduction of newer compounds (i.e., synthetic pyrethroids), as well as
Environmental Protection Agency (EPA) bans/restrictions, have decreased the usage
of OP insecticides in recent years, they are still frequently used in agriculture.

3

The Food Quality Protection Act of 1996 mandates that all pesticides that act
through a common mechanism of toxicity undergo cumulative risk assessments. The
concern is that exposure to multiple members of a common-mechanism group might
pose a health risk even if the individual components of the mixture are present at
levels below their respective no-observed-adverse-effect levels. A working group of
experts determined that chemicals that act via a common mechanism of toxicity must
satisfy three specific points. The chemical must (1) cause the same critical effect (2)
by action through the same biochemical mechanism (3) on the same molecular target
or target tissue (Mileson, 1998). OP insecticides were the first class of chemicals to
undergo a cumulative risk assessment (US EPA, 2002). They share a common
mechanism of toxicity, the inhibition of acetylcholinesterase (AChE), resulting in
accumulation of acetylcholine in cholinergic synapses and excessive stimulation of
cholinergic pathways in central and peripheral nervous tissues. Gearhart et al. (1990)
has suggested that PBTK/TD models capable of predicting the relationship between
OP insecticide exposure and AChE inhibition are useful for evaluating the risk
associated with a given exposure. The EPA is in the early stages of developing a
strategy for incorporating PBTK/TD models into its cumulative risk assessments. A
limited number of PBTK/TD models for OP insecticides have been published in the
literature (Maxwell et al., 1988; Gearhart et al., 1990; Sultatos, 1990; Abbas &
Hayton, 1997; Timchalk et al., 2002; El-Masri et al., 2004; Poet et al., 2004;
Timchalk et al., 2005); at present, no models exist for ternary mixtures of OP
insecticides.
4

Mixture Components
Although uses of OP insecticides have been greatly restricted and/or banned
in the United States in recent years, they still remain a potential concern to human
health due to continuing world-wide use. In addition, all three OP compounds used in
the present study were on the 2003 Comprehensive Environmental Response,
Compensation, and Liability Act (CERCLA) Priority List of Hazardous Substances,
further highlighting the need for concern.
The nomenclature of OP insecticides is dependent on the type of atoms
directly bonded to the phosphorus atom; principally oxygen and sulfur, with nitrogen
and carbon present to a lesser extent. A major class of commonly used OP
insecticides are the phosphorothionates, where three of the atoms surrounding the
phosphorus are single bonded oxygen and the other is a coordinate covalent bonded
sulfur (P=S). Chlorpyrifos, methyl parathion and parathion are phosphorothionate
insecticides. Chlorpyrifos and parathion contain structural similarities (both diethyl
compounds), as shown in Figure 1; however parathion is approximately 10-fold more
toxic to mammals than chlorpyrifos. The oral LD50 for chlorpyrifos is 82-155mg/kg
in rats, while the rat oral LD50 for parathion is 3-17mg/kg (Kidd & James, 1991).
Methyl parathion (Figure 1) differs structurally (a dimethyl compound) as compared
to chlorpyrifos and parathion, but is similar in acute toxicity to parathion (oral LD50
for methyl parathion is 14-24mg/kg in rats; Kidd & James, 1991).

5

Mechanism of Inhibition
AChE, the primary target for OP compounds, is responsible for the rapid
hydrolysis of acetylcholine (ACh), a neurotransmitter involved in the numerous
cholinergic pathways in the body; central and peripheral nervous system (somatic
nervous system innervating skeletal muscles and both the sympathetic and
parasympathetic divisions of the autonomic nervous system). As long as the active
site of AChE is phosphorylated, it is inhibited. The phosphorylated enzyme is no
longer capable of hydrolyzing ACh, which results in accumulation of ACh in
cholinergic synapses and excessive stimulation of the ubiquitous cholinergic
pathways (Murphy, 1986; Sultatos, 1994). Clinical manifestations of overstimulation
of cholinergic pathways include hyper-salivation, lacrimation, vomiting, urination
and diarrhea. Central nervous system effects include anxiety, restlessness, dizziness,
confusion, ataxia and convulsion. One of the most significant consequences of AChE
inhibition is depression of cardiopulmonary function. Death is generally attributed to
respiratory failure resulting from a combination of central and peripheral effects;
specifically bronchiolar constriction, enhanced bronchiolar secretions, paralysis of
respiratory muscles, and respiratory control center shut-down in the brain. Because of
the severity of these effects, the vital importance of these target systems to
maintenance of life, and the rate with which many of the OP insecticides act,
incapacitation and death can occur quickly. Symptoms are more-or-less severe,
depending on the OP compound, dose, route, frequency and duration of exposure.
6

Short-term exposure to OP insecticides may also have long-term consequences,
ranging from changes in behavior to prolonged or delayed peripheral neuropathy and
myopathy (Savage et al., 1988; Rosenstock et al., 1991).
Structurally, AChE contains two sites, an esteratic site and an anionic site.
AChE uses both sites to attach ACh with the quaternary nitrogen of ACh interacting
with the negatively charged anionic site, thereby orienting the carbonyl group into the
active site. Once present at the active site, AChE hydrolyzes ACh and releases
choline. This hydrolysis produces an acylated enzyme which undergoes rapid
hydrolysis to return to its original form. Anticholinesterases (OP insecticides) may
interfere with the hydrolysis of ACh by attachment to AChE at the esteratic site.
Generally, the majority of OP insecticides phosphorylate AChE at the serine group of
the esteratic site. The ability of an OP compound to bind to AChE depends on the
nucleophilicity of the active site. While the serine group is the primary site of
phosphorylation, the imidazole of the histidine residue in the active site enhances the
nucleophilicity of the active site by forming a hydrogen bond between itself and the
serine hydroxyl. It is this interaction which promotes the binding of C=O of the ACh
and P=O of the OP insecticide to the active site. Once the ACh is bound and choline
is cleaved, the conformational changes favor the rapid release of the acyl group,
hence reactivating the enzyme. However, with OP insecticides, the release of the
phosphorylated group from the serine hydroxyl is quite slow, leading to long-term
inhibition of the enzyme (Silver, 1972). The ability of an OP insecticide to interact
with the enzyme depends on the electrophilicity of the inhibitor. The nucleophilic
7

attack (transesterification) of the serine hydroxyl by the phosphorus atom is
dependent on the electrophilic properties of the enzyme and the inhibitor (Wallace,
1992). The OP will associate with the anionic site and this association allows the
phosphorylation of the active site. Once phosphorylated, the portion of inhibitor that
is associated with the anionic site is cleaved. This cleaved group is called the “leaving
group”. The anionic site may function to orient the inhibitor such that association
with the nucleophilic active site is preferable for some inhibitors compared with
others. The basis for this inhibitory preference may be either the distance between the
anionic site and the esteratic site, or the electronic properties of the leaving group.
Once formed, the phosphorylated enzyme can undergo spontaneous
reactivation, however this is quite slow, and in some instances depending on the
groups attached to the phosphorus atom, it can be irreversibly inhibited. Reactivation
involves dissociation of the enzyme-inhibitor complex, consequently breakage of a
covalent bond. Although the spontaneous reactivation of cholinesterases is slow, the
addition of other compounds, specifically hydroxylamine and choline, to an inhibited
cholinesterase preparation can decrease the time required for reactivation to occur
(Wilson, 1952). The hydroxylamine is referred to as a “reactivator”, and a great deal
of research has been undertaken on related compounds. The reactivators are
nucleophilic compounds with a high affinity for phosphorus. The most efficient
reactivators are those which possess a strong ionizable oxime group (=NOH),
preferably the bis-pyridinium-aldoximes (Hobbiger and Sadler, 1959). Included
among the bis-pyridinium-aldoximes are the salts of pyridine 2-aldoxime or 2-PAM,
8

which are used clinically. The potency of the oximes is attributed to the binding of the
quaternary nitrogen to the enzyme and the positioning of the highly nucleophilic
oxime moiety such that it supports the transfer of the enzyme-bound phosphate from
the enzyme to the oxime (Wilson et al., 1992). Once the phosphate is removed, the
cholinesterase’s hydrolytic activity returns. However, not all inhibited cholinesterases
are capable of being reactivated by oximes. Following the development of
reactivators, it was shown that inhibited cholinesterase would remain inhibited even
following removal of the excess inhibitor. The capacity to chemically reactivate the
inhibited cholinesterase is lost over time. The process is termed “aging” of
cholinesterase, and the mechanisms behind this phenomenon were elucidated using
the potent anticholinesterase, DFP (diisopropyl fluorophosphate). Various noncholinesterase enzymes inhibited by DFP were mildly degraded and were shown to
have diisopropyl groups attached to their serine groups. However, DFP-inhibited
cholinesterase yielded not only diisopropyl phosphorylated serine groups but also
monoisopropyl phosphorylated serine groups, suggesting a change in the diisopropyl
moiety attached to the enzyme to form a monoisopropyl moiety. The hydrolysis of the
isopropyl group off the phosphorus atom attached to the enzyme converted the
enzyme to a non-reactivatable form. Using enzyme inhibited with the radiolabled
nerve gas, sarin, Harris et al. (1966) demonstrated that the loss of the alkyl group
from the phosphorylated enzyme correlated with the amount of the enzyme that was
not responsive to reactivation by an oxime. The importance of dealkylation in aging
was further substantiated by Beauregard et al. (1981) using radiolabeled DFP9

inhibited AChE. This dealkylation stabilized the phosphate-enzyme complex, thus
preventing both spontaneous and chemical-induced reactivation (Wilson et al., 1992).
The rate of reactivation and aging depends on the geometry of the groups
attached to the phosphorus atom. This has been established using stereoisomers of
sarin (Berends, 1964) in which some stereoisomers differ greatly in their rate of aging
compared to others. Clothier et al. (1981) demonstrated that there are differences in
the rates of reactivation and aging of AChE when the alkyl groups attached to the
phosphorus differ. Dimethoxy-substituted OP compounds reactivate and age faster
than those that are diethoxy-substituted. It was shown that the amount of aging
increased when the oxygen atoms in the dimethoxy and diethoxy groups around the
phosphorus atom were replaced with sulfur atoms (Langenburg et al., 1988). Since
substitution of different groups can change the electrophilic properties of the
inhibitor, aging not only can be affected but inhibitory potency also. Contribution of
the anionic site to aging has also been suggested. As mentioned previously, the
association of the inhibitor with the anionic site can influence the phosphorylation of
the active site.

Metabolic Activation
Chlorpyrifos, methyl parathion, and parathion do not directly inhibit AChE,
but must first be metabolically activated, by oxidative desulfuration (P=S to P=O) to
chlorpyrifos-oxon, methyl paraoxon and paraoxon, respectively. The activation of
chlorpyrifos, methyl parathion, and parathion to their oxons is mediated by
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cytochromes P450, principally within the liver. However, extrahepatic metabolism
has been reported in other tissues, including brain (Chambers & Chambers, 1989). All
three phosphorothionates can be detoxified by P450’s in a dearylation reaction to
dialkyl phosphate or dialkyl phosphorothionate plus the alcohol (3,5,6-trichloro-2pyridinol (TCP) for chlorpyrifos, 4-nitrophenol for methyl parathion and parathion).
Differences in the ratio of activation to detoxication are thought to be related to the in
vivo levels of sensitivity to OP insecticides (Ma and Chambers, 1994). Hepatic and
extrahepatic A-esterases can effectively metabolize chlorpyrifos-oxon to TCP and
diethylphosphate (Sultatos & Murphy, 1983). B-esterases, such as carboxylesterase
(CaE) and butyrylcholinesterase (BuChE) can likewise detoxify chlorpyrifos-oxon;
however the B-esterases become irreversibly phosphorylated (1:1 ratio) by
chlorpyrifos-oxon and consequently become inactivated (Clement, 1984). Paraoxon
also reacts irreversibly with CaE and BuChE. In contrast to paraoxon and
chlorpyrifos-oxon, hepatic CaEs are not very sensitive to methyl paraoxon in vitro, so
a large portion of methyl paraoxon generated in the liver may be able to exit the liver
and reach the target sites causing AChE inhibition (Chambers et al., 1989).
Inactivation of non-critical esterases produces no known toxic effect. CaE is
present in many tissues including liver, kidney, intestine, plasma and muscle (Satoh,
1987). This serine esterase catalyzes the hydrolysis of carboxylesters. BuChE occurs
predominately in the plasma. The phosphorylation of the serine hydroxyl groups of
CaE and BuChE by chlorpyrifos-oxon and paraoxon is important as a detoxication
process, which stoichiometrically reduces the amount of both oxons available to
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inhibit AChE (Maxwell, 1992). In addition to the enzymatic detoxication of OP
insecticides, reactivation of the phosphorylated AChE also plays an important role in
recovery of the active enzyme. As mentioned earlier, phosphorylated AChE
undergoes spontaneous hydrolysis, but the rate depends on the nature of the alkyl
substitutions. In the case of chlorpyrifos-oxon, methyl paraoxon and paraoxon, the
rate of dephosphorylation is very slow. Dealkylation of the phosphoryl-cholinesterase
complex may also occur, resulting in an aged enzyme, as stated previously, that does
not readily undergo spontaneous reactivation (Berends et al., 1959). Cholinesterase
lost to aging is replaced through the synthesis of new enzyme. Changes in the relative
contributions of reactivation and replacement may explain the biphasic recovery of
cholinesterase activity following oral administration of some OP compounds (Benke
et al., 1974; Hahn et al., 1991; Chambers & Carr, 1993). Spontaneous reactivation
may be more important during the initial, faster phase of recovery, whereas synthesis
of new enzyme has a greater role during the later, slower phase of recovery. The
balance between aging, inactivation, reactivation, and replacement determines the
pattern of cholinesterase inhibition following OP compound exposure. Ultimately,
these parameters are determined as much by route-of- administration/exposure as by
dose.
Toxicodynamic processes alone, however, do not determine OP insecticide
potency; equally important are toxicokinetic characteristics. For most OP compounds,
absorption is rapid and complete, via oral or inhalation exposure, and distribution is
typically quite extensive. The overall balance between metabolic generation and
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elimination of more- versus less-toxic derivatives is a major factor that determines
potency. For example, differences in the overall rates of detoxication contribute to the
greater sensitivity of female rats to some OP compounds (chlorpyrifos, methyl
parathion, parathion) as compared to male rats, and to the greater sensitivity of young
animals compared to adults (Ma and Chambers, 1995; Chambers et al., 1994;
Atterberry et al., 1997). In addition, differences in the overall balance between
generating and eliminating more versus less toxic derivatives following oral
exposures compared to inhalation exposures, due to first-pass hepatic metabolism,
can contribute to differences in potency for the same compound when administered
via different routes.

Chlorpyrifos
Chlorpyrifos (CP) (O,O-diethyl-O-[3,5,6-trichloro-2-pyridyl]
phosphorothioate) is one of the most widely used OP insecticides. It is currently used
on more than 40 different agricultural crops; its prior uses as a termiticide, residential
indoor and lawn insecticide has been phased out/eliminated. CP has been registered
for use in 88 countries with more than 100 indications for treating crop and urban
environments and marketed under approximately 359 labels worldwide with over two
dozen formulation types (Albers et al., 1999). The average daily intake of CP for
humans has been reported to be 0.01mg/kg/day (Lu, 1995). CP is well absorbed
orally; approximately 90% of orally administered CP is eliminated by rats in urine by
48-66 hours after dosing. The remaining 10% is eliminated in the feces. CP is
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eliminated almost exclusively in the urine as TCP (3,5,6-trichloro-2-pyridinol).
Elimination half-lives for liver, kidney, muscle, and fat are 10, 12, 16, and 62 hours,
respectively, indicative of considerable storage in fat (Smith et al., 1967).
CP is metabolized to CP-oxon via cytochrome P450-dependent desulfuration.
The oxon is rapidly hydrolyzed to TCP via microsomal esterases (including
paraoxonase and CP oxonase) or via nonenzymatic processes (Sultatos et al., 1983;
Costa et al., 1990). Alternatively, CP can be dearylated to form diethyl
thiophosphoric acid and TCP in a reaction also catalyzed by microsomal enzymes.
TCP or one of its conjugates, is almost exclusively (90%) excreted in the urine
(Bakke et al., 1976), as mentioned above. CP-oxon binds to and irreversibly inhibits
AChE. However, the relative affinity of CP-oxon for plasma and hepatic esterases
exceeds that for AChE. Furthermore, CP-oxon causes relatively greater and longer
lasting inhibition of hepatic esterases in vivo compared to brain AChE (Chambers and
Carr, 1993). Noncatalytic binding of CP-oxon to hepatic and plasma esterases
represents a significant detoxication mechanism because it prevents much of the
hepatically generated CP-oxon from entering the general circulation and target
tissues. High rates of hepatic dearylation and esterase binding may represent
protective factors. However, CP can be activated in extrahepatic tissues, such as brain
(Chambers and Chambers, 1989). Comparative difference in the rates of hepatic
esterase binding and rates of dearylation have been implicated as contributors to the
greater sensitivity of some tissues (i.e., brain) to CP, compared to other tissues, and to
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the greater toxicity of parathion, discussed below, compared to CP (Chambers et al.,
1990; Pond et al., 1995).

Methyl parathion
Methyl parathion (MP) (O,O-dimethyl O-p-nitrophenyl phosphorothioate)
may only be used legally on certain agricultural crops; it is most commonly used on
cotton. Other major uses include corn, peaches, wheat, barley, soybeans and rice.
There has been great concern regarding the illegal indoor use of methyl parathion
products in private homes and other structures. Such use posed potentially significant
health risk to individuals who lived or frequented such indoor areas and has resulted
in significant relocation and cleanup costs in several states. Absorption, distribution,
and elimination of MP via oral exposure is rapid and extensive. For example, MP is
rapidly absorbed in rats, concentrations in blood and brain are maximal in 1-3 hours,
and nearly completely eliminated in urine (mostly as dimethyl phosphoric and
dimethyl phosphorothioic acid) by 7 days (Miyamoto et al., 1963). In addition,
following oral exposure, MP is widely distributed to blood, liver, adipose tissue,
muscle and brain. Distribution coefficients are highest in adipose tissue 8 days after
exposure (0.99), in liver 20 days after exposure (0.17), and in brain 16 days after
exposure (0.35), but they are < 1.0, indicating no long-term accumulation of MP in
tissues. Half-lives of elimination are 15 days for blood, 13 days for adipose tissue, 15
days for liver, and 15 days for brain (Garcia-Repetto et al., 1997).
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MP is oxidatively desulfurated to methyl paraoxon or dearylated to dimethyl
thiophosphorothioic acid and 4-nitrophenol via cytochrome P450 enzymes. MP-oxon
can also be dearylated to dimethyl phosphoric acid and 4-nitrophenol and hydrolyzed
to O-methyl-O-p-nitrophenyl phosphate. All of these oxidative and hydrolytic
products are excreted in urine (Hollingworth et al., 1967). These metabolic
conversions occur principally within the liver, but can also occur in the lung and
brain. MP-oxon binds to and irreversibly inhibits AChE. Noncatalytic, stoichiometric
binding to other esterases (aliesterases) in liver and plasma also occurs, however, and
may represent a significant detoxication mechanism, since it can reduce the amount
of MP-oxon that leaves the liver and/or blood to enter target tissues. Binding to
hepatic and plasma esterase may not be as significant a detoxication mechanism for
MP as it is for CP and parathion (P), however, because the affinity of MP-oxon is
considerably greater for brain AChE than for hepatic esterase; the reverse is true for
CP and P. Consequently, even though MP-oxon has a lower affinity for AChE than Poxon, the relatively weaker protection afforded by the aliesterases can permit lethal
levels of hepatically generated MP-oxon to reach the nervous system (Chambers and
Carr, 1993).

Parathion
Parathion (P) (O,O-diethyl O-p-nitrophenyl phosphorothionate) is one of the
most toxic insecticides registered with the EPA. It is used as a pre-harvest soil and
foliage treatment on a wide variety of crops. In 1992 the EPA cancelled all uses of P
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on fruit, nut and vegetable crops. However, P is still used on alfalfa, barley, corn,
cotton, sorghum, soybeans, sunflowers and wheat. As one of the earliest and
efficacious OP insecticides, P possesses a substantial database. Once absorbed, P is
widely distributed regardless of the route of exposure. Distribution coefficients are
highest in the liver (4.1-20.8) and adipose tissue (1.3-2.9) but also exceed 1 in the
brain (1.0-1.4) and muscle (1.5-1.9) (Garcia-Repetto et al., 1995). P can be converted
to P-oxon by cytochrome P450 enzymes. Alternatively, P can be dearylated to form
diethyl phosphorothioic acid and 4-nitrophenol in a reaction catalyzed by microsomal
enzymes. P-oxon can also be dearylated to diethyl phosphoric acid or hydrolyzed to
O-ethyl-O-4-nitrophenyl phosphate. 4-nitrophenol, the primary metabolic product
formed from P, is eliminated in the urine and quantifying it can provide an index of P
exposure. These metabolic conversions occur principally in the liver, but also in the
lung and brain. P-oxon binds to and irreversibly inhibits AChE; binding to other
hepatic and plasma esterases also occurs, however, and can represent a significant
detoxication mechanism since it prevents much of the hepatically generated P-oxon
from entering the general circulation and target tissues.

PBTK/TD Models
Although physiological aspects of disposition of compounds by organs within
the body had received attention earlier in history, it was not until 1937, with the
significant work of Teorell, that an integrated approach to whole-body
physiologically-based modeling of pharmacokinetics received serious consideration.
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However, due to the mathematical and computational complexities and the lack of
some basic physiological information at the time, whole-body PBTK/TD modeling
did not come of age until the 1960’s, when, with the aid of the digital computer, and
modeling contributions from the chemical engineering community, interest
reawakened in this area. As a means of overcoming many of the problems that plague
classical compartmental models, which are basically abstract mathematical
constructs, lacking actual anatomical, physiological, and biochemical relevance,
Bischoff and Dedrick (1968) introduced PBTK/TD models as an alternative.
Pharmacokinetic models range from simple empirically-based models that
describe observed data, to more complex PBTK/TD models that can be used to
predict outcomes and extrapolate from one set of exposure conditions to another
based upon an understanding of the underlying biology. PBTK/TD models for
mixtures are significant tools for predicting conditions under which interactions are
likely to alter assumptions of additivity and permit calculation of interaction
thresholds with greater confidence. A PBTK model is a quantitative description
(typically with differential equations) of the biological structures and processes that
control toxicokinetic (TK) behavior in an organism (i.e., the effect of the body on the
absorption, distribution, metabolism, and excretion of a chemical). PBTK modeling
differs from classical compartmental PK modeling in this focus on the biological
determinants of PK behavior. PBTK models simulate the events between the external
dose and the internal exposure of the chemical to a target site. PBTD (toxicodynamic)
models address the events from the internal dose at the target site to the response
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observed (i.e., the effect(s) of the chemical on the body; inhibition of AChE in the
present study). PBTK/TD models are used to establish a connection between TK
behavior and the biological or toxicological effect of a chemical on the body. Thus,
while classical empirical modeling is useful for interpolation between data points, a
well developed PBTK/TD model can be used to simulate toxicological outcomes for a
variety of different exposure conditions (different test species, exposure routes,
chemical concentrations, metabolizing capacities).
Development and use of PBTK/TD models requires knowledge of organismspecific and chemical-specific biologic processes. An understanding of the
parameters that govern the toxicokinetics is also essential. Proper development and
use of these models often requires examination of existing data, model formulation,
and testing leading to more specific data requirements, which in turn leads to model
refinement. These capabilities allow PBTK/TD models to serve two different roles.
First, the models can play a major role in the laboratory study of toxicokinetics and
mechanism-of-action. This particular role of PBTK/TD models is especially powerful
when model development and laboratory experiments are conducted in an iterative,
mutually supportive manner. Models can help identify key data which are lacking,
elucidate important events in the processes leading to toxicity, and also identify and
quantify uncertainty. For example, PBTK/TD models may illuminate nonlinearities in
high-to-low dose extrapolation, and interspecies scaling factors that perhaps would
not be apparent without a quantitative, mechanistic perspective. A second important
role of PBTK/TD models is in the development of risk assessments. PBTK/TD
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models developed from an adequate supporting database that have been validated,
demonstrate reasonable ability to predict the behavior of data sets NOT used during
model development, can be used for partial or complete replacement of the default
assumptions used in risk assessment (i.e. intra- and inter-species extrapolation factors
or route-to-route extrapolation). Once a PBTK/TD model is defined in one animal
species, it can be used for humans by replacing the physiological, anatomical,
biochemical, and thermodynamic variables used for the experimental animal, with the
values for the corresponding parameters from humans. The accuracy of the model
depends on the blood and tissue solubility, metabolism, and protein binding
characteristics in various tissues and the physiology of the organism. The aim of the
acute simulations for the present study was to reproduce experimental data from in
vivo dosing studies NOT used in development of the model. Good agreement between
the model and experimental results allow one to have greater confidence in
extrapolating.

Mixtures
Toxicokinetic interactions may involve alterations of the absorption,
distribution, metabolism, or elimination phase of one or more chemicals due to the
influence of another chemical. There are numerous literature examples of absorption
and elimination phase interaction, the vast majority of which occur at high dose levels
however. Likewise, interactions affecting distribution, such as competition for protein
binding and tissue saturation effects, are unlikely to occur at exposure concentrations
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relevant for human exposures (Poulin & Krishnan, 1996). Thus, interaction at the
metabolic level represents the most probable mechanistic basis for a number of
interactions observed in chemical mixtures at environmentally relevant exposure
levels.
The metabolism of individual OP insecticides has been well characterized;
however, there is a lack of data regarding the in vitro/in vivo inhibition of ChE by
combinations of OP compounds. A limited number of studies (DuBois, 1969; Karanth
et al., 2001, 2004; Hazarika et al., 2003) have characterized the toxicological effects
of exposures to binary OP insecticide mixtures. Even so, many of these studies do not
address the larger issue of cumulative exposures to mixtures of pesticides at more
realistic lower dosage levels. Keplinger and Deichmann (1967) found that exposure
of laboratory animals to mixtures of ChE-inhibiting insecticides resulted in greater
than additive effects on acute toxicity in vivo. However, a recent in vivo study by
Timchalk et al. (2005) with binary mixtures of chlorpyrifos and diazinon showed that
low-level binary mixtures exhibit additive responses with respect to ChE inhibition.
Furthermore, Tahara et al. (2005) using an in vitro methodology, evaluated the
toxicity of multiple binary combinations OP oxons based on the degree of inhibition
of ChE activity, found the degree of inhibition was also generally additive. Similarly,
a previous in vitro study in our laboratory (Richardson et al., 2001), with a binary
mixture of chlorpyrifos-oxon and azinphos-methyl-oxon, noted dose additivity when
both compounds were added simultaneously to brain tissue. More recently, Gordon et
al. (2006) reported an antagonistic effect on rat brain ChE between the insecticides
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chlorpyrifos and the carbamate carbaryl when administered in a 1:1 ratio, whereas a
2:1 mixture had additive effects on brain ChE. They suggested this resulted from the
depletion of key detoxication esterases not directly associated with neural function.

Justification and Hypotheses
While there are approximately 30 commercially relevant OP insecticides,
three such compounds were selected for the following reasons: coding, running, and
validating a PBTK/TD model for more than three OP compounds would have
presented unwarranted significant challenges given the present state-of-knowledge.
Sufficient literature exists to support the development of a ternary mixture model
using CP, MP, P, whereas insufficient data are available for other OP insecticides.
However, mechanistic data on other OP insecticides could be incorporated within the
current PBTK/TD model in the future for the extrapolation of the interactions of more
complex mixtures once sufficient data are made available, since they share a similar
toxic mechanism-of-action. Finally, the selection of the three OP insecticides in the
present study are particularly valuable for the kinetic and dynamic analyses, since the
onset-of-action, peak-effect, and the duration-of-action can be studied over a
relatively short period of time (24hr); this is quite important in the collection of
experimental data to validate the model since experimental techniques involved with
the animals are extensive/time consuming.
The primary objectives of the current study were to: (1) develop and validate a
PBTK/TD model that can be used to successfully predict the toxicokinetic disposition
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and toxicodynamic response (ChE inhibition) of a ternary OP insecticide mixture:
chlorpyrifos, methyl parathion and parathion; (2) test the assumption of additivity
(ChE response), in linking the individual models (only single-compound models were
used, no parameters specific for interaction effects were added to the models); (3) the
existing database of PBTK/TD models for chemical mixtures is sparse; this study
helps to expand that database. Furthermore, this model provides a strong foundation
for future PBTK/TD model development of more complex OP insecticide mixtures.
Chapter II describes the processes involved in developing the PBTK/TD model.
Chapter III and IV describe the in vivo toxicokinetic and toxicodynamic studies,
respectively, used to validate the PBTK/TD model. Lastly, Chapter V addresses
general conclusions of the study.
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Chlorpyrifos

Methyl Parathion

Parathion

Figure 1.1. Structures of chlorpyrifos, methyl parathion, parathion.
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CHAPTER II
MODEL DEVELOPMENT

The PBTK/TD model was written as a program, using acslXtreme®
Pharmacokinetic Toolkit Version 1.4 (AEgisTechnologies Group, Inc., Huntsville,
AL), on a personal computer. Advanced Continuous Simulation Language (ACSL), is
designed for modeling and evaluating the performance of continuous systems
described by time-dependent, nonlinear differential equations. An important feature
of ACSL is its sorting of continuous model equations, in contrast to digital
programming languages such as FORTRAN where program execution depends on
statement order. The Pharmacokinetic Toolkit®, used in concert with ACSL, is a
collection of specialized PowerBlocks™ (PBTK/TD equations), that can be joined to
model complex physiological processes. ACSL is commonly used in both
pharmacology and toxicology for applications such as dosimetry, risk assessment,
parameter estimation, and is cited extensively in the PBTK/TD modeling literature.
There are other commercially available simulation software packages (SCoP®,
STELLA®, PPP®, WinSAAM®, WinNonLin®; however, none are as user-friendly nor
as comprehensive as acslXtreme® Pharmacokinetic Toolkit.

25

PBTK/TD Model Development Approach
PBTK/TD models have been developed for two of the individual compounds
(Timchalk et al., 2002 (chlorpyrifos)), (Sultatos, 1990 (parathion)) used in the present
study; making them ideal candidates for investigating mixture interactions without
having to develop or validate a new PBTK/TD model for each compound.
Nevertheless, a number of refinements were required for each model in order to
construct a PBTK/TD model of predictive utility for the ternary mixture. Different
modeling approaches (differences in parameters and underlying assumptions in the
model structures, species used, sources for biological data etc.) were used for the
models cited above. Therefore, the models could not simply be merged together as is.
Thus, the ternary PBTK/TD model is a hybrid in essence, composed of the “best”
parts of the two models, incorporating the needed changes to link the models under
the assumption of additivity of ChE response. The PBTK/TD model for chlorpyrifos
(Timchalk et al., 2002) served as a template, since this model was comparatively
robust, requiring the least refinement of the two.
Given the importance of methyl parathion, discussed in Chapter I, the
similarities/ differences in chemical structure and toxicity, as compared to
chlorpyrifos and parathion, made its inclusion as the third OP insecticide of interest in
the model a logical choice even though a PBTK/TD model has not been developed
for methyl parathion. Sufficient literature, notably a somewhat recent review article
of the pharmacokinetics and pharmacodynamics of methyl parathion by Kramer and
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Ho (2002), and data from our laboratory allowed methyl parathion to be adequately
modeled with chlorpyrifos and parathion.

Model Structure
The model consists of both organ-specific and lumped compartments. Organspecific compartments were used to describe tissues directly involved in acute OP
toxicity (i.e., brain, diaphragm, etc.) or tissues expected to significantly influence the
toxicokinetics (blood, fat). The use of lumped compartments in the model helped to
preserve a balance between parsimony of model structure, to maintain chemical mass
balance, and to explicitly describe the physiology and biochemistry that determine the
toxicokinetic behavior of the compounds. The model describes the time-course of
absorption, distribution, and metabolism of chlorpyrifos, methyl parathion, parathion,
their respective oxons, and detoxication products, as well as the inhibition of ChE by
each oxon. As mentioned above, the two models were not merely “linked” as is, due
to differences in modeling approaches used by each investigator and the need to
eliminate redundancies between the two models, in order to construct a more efficient
modeling system.
Figure 2.1 shows the resulting “hybrid” ternary mixture model, which
describes the rat as a network of 6 tissue compartments; namely, adipose tissue, brain,
diaphragm, liver, rapidly perfused tissues (representing viscera not explicitly
described), slowly perfused tissues (primarily denoting muscle tissue), interconnected
by systemic circulation and lung. The overall model consists of six PBTK/TD
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models, 3 for the parent chemicals (chlorpyrifos, methyl parathion, parathion) and 3
for the oxon metabolites of each chemical. Each metabolite model is linked to its
parent chemical model via the liver compartment. This is accomplished by
considering the production rate of the metabolite as a reservoir for the parent
chemical and as a source for the metabolite model. The estimated levels of the
metabolites are then linked to a sub-model for AChE kinetics describing enzyme
synthesis, degradation, inhibition and aging. The sub-model of AChE kinetics
consists of 3 compartments, describing the mass balances for the free, inhibited, and
aged forms of AChE.
For solving the equations in the ternary mixture model, a single set of rat
physiological parameters and 3 sets of chemical-specific parameters (metabolic rates
and partition coefficients for each compound) were used. These data were obtained
from the literature. The model assumes that the toxicokinetic and toxicodynamic
response in rats is independent of gender; the majority of the model parameters are
based on those obtained from male rats, however. The absorption of the parent
compounds, following oral gavage exposure, required the use of a two-compartment
uptake model to simulate absorption. The two-compartment model incorporated 1storder rate equations to describe systemic uptake and transfer between compartments.
The cytochrome 450 (CYP)-mediated activation and detoxication of the compounds
was limited to the liver compartment. The parent compound models were linked to
the oxon models that contained equations to describe the A-EST hydrolysis in both
the liver and blood compartments. The CYP activation/detoxication and A-EST
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detoxication were all described as Michaelis-Menton processes. Interactions of the
oxon with B-EST (AChE, BuChE, and CaE) were modeled as 2nd-order processes
occurring in the blood, brain, diaphragm and liver. The B-EST enzyme levels in
blood, brain, diaphragm, and liver were calculated based on the enzyme turnover
rates and enzyme activities reported by Maxwell et al. (1987), which were based on a
balance between basal degradation and enzyme resynthesis. Following exposure to
the respective oxons, the amount of available B-EST was determined by finding a
balance between the bimolecular rate of inhibition and rate of B-EST regeneration
(reactivation and resynthesis). In the present model, the detoxication products were
formed by direct CYP metabolic conversion of the parent compounds and through AEST mediated hydrolysis of the oxons and B-EST binding of the oxons. The selection
of a reasonable set of model parameters was determined by evaluating the overall
goodness of fit of the model against experimental data over the range of reported rate
constants for enzyme affinities and activities.
In the current model, the total amount of absorbed parent compound is
directly added to the liver compartment. However, once in the systemic circulation,
only non-bound parent compound or metabolite was capable of entering the tissue
compartments. The model structure for the inhibition of ChE by the compounds
(oxons) in the selected tissues was based on the model structure developed by
Gearhart et al. (1990), as modified by Timchalk et al. (2002). Since chlorpyrifos,
methyl parathion, and parathion are all phosphorothionates, model parameters for
chlorpyrifos reactivation and aging were also used for methyl parathion and
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parathion, since the reactivation rates are similar, and aging is solely dependent on
enzyme kinetics, regardless of the compound. Interactions between the compounds
were explicitly described in the model at the level of metabolism through competition
with CYP enzymes in the liver. At the response level, additivity of ChE response was
assumed.
One of the objectives of the present study was to determine if the ternary OP
mixture could be modeled solely using single-compound parameters; i.e., to address
whether it is necessary to introduce separate interaction parameters for a mixture, as
has been suggested by Tardif et al. (1997). As will be demonstrated in Chapters III
and IV, a PBTK/TD mixture model can be successfully developed without the need
for interaction experiments (i.e., explicit binary-interaction studies), at least in the
case of simulations of low-dose exposures to a ternary OP insecticide mixture. The
design of the current PBTK/TD model is sufficiently general and flexible in nature,
such that it has the advantage of being applicable in the future to a variety of OP
insecticides with minimal data input required. The model code is presented in
Appendix A.
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Figure 2.1. Schematic diagram of the ternary PBTK/TD mixture model. The model consists
of six PBTK/TD models; 3 for the parent chemicals (chlorpyrifos, methyl
parathion, parathion) and 3 for the metabolites of each chemical (their
respective oxons). Each metabolite model is linked to its parent chemical model
via the liver compartment. The metabolite models are linked to a sub-model for
AChE kinetics; consisting of 3 sections describing the mass balances for free,
inhibited, and aged forms of AChE.
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CHAPTER III
MODEL VALIDATION: TOXICOKINETIC ANALYSES

Introduction

The principal objective of PBTK/TD modeling is prediction. In order to have
confidence in the predictive power of a PBTK/TD model, the model must be
validated. Model validation is a process in which the model's predictions are
compared with experimental data NOT used in the creation of the model. Model
validation is aimed only at demonstrating whether a model can produce reasonable
accuracy within its realm of applicability, not that it embodies absolute truth, nor that
it is the “best” model available. A model can never be proven wholly valid, only
invalid.
The potential toxicity of an OP insecticide mixture is dependent upon several
factors, namely, the amount delivered to the target tissue(s) and the balance between
activation and detoxication. Toxicokinetic studies can provide important information
on absorption, tissue compartmentalization of the parent compounds and their
respective metabolites, and the time-course of compound transfer from one tissue
compartment to another. Such information is central to fully describing the
distribution, fate, and potential interaction patterns of each chemical within a mixture.
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The objective of this portion of the study was to characterize the dosimetry of the
parent compounds, their respective oxons, and detoxication products in selected
tissues following oral gavage exposure to the ternary OP insecticide mixture.

Materials and Methods

Chemicals
Analytical grade chlorpyrifos, chlorpyrifos-oxon, methyl parathion, methyl
paraoxon, parathion, paraoxon, 4-nitrophenol, TCP, and nitrophenyl valerate were
provided by Dr. Howard W. Chambers, Department of Entomology and Plant
Pathology, Mississippi State University, and were synthesized as previously
described (Chambers et al., 1990). Analytical grade parathion and methyl parathion
were re-crystallized from a generous gift from Monsanto Company (St. Louis, MO).
Analytical grade chlorpyrifos and 3,5,6-trichloro-2-pyridinol, for synthesis of
chlorpyrifos-oxon, were a generous gift from DowElanco Chemical (Indianapolis,
IN). The same batch of each chemical was used throughout the study. Analytical
grade ethyl acetate and acetonitrile were purchased from Burdick and Jackson (VWR
International, West Chester, PA). Optima grade methanol was purchased from Fisher
Scientific (Hampton, NH). All other chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO).
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Animals and Treatments
Adult male Sprague-Dawley rats [Crl:CD(SD)BR] (280-330g) were obtained from
Charles River Laboratories, Inc. Animals were housed in an AAALAC accredited
facility and maintained in a temperature controlled room (22 ± 1oC), 12:12 hour
light/dark cycle, with food and water available ad libitum. Prior to dosing, food was
withheld overnight (12hr) to allow for gastric emptying to minimize absorption of the
mixture components by stomach contents following oral gavage administration. The
Mississippi State University Animal Care and Use Committee approved all
procedures.

Optimization-Dosage Range Finding
A pilot study was undertaken in order to determine the optimal dosage(s) for the
mixture components used in the formal validation experiments, i.e., the dosage of
each compound which was sufficient in magnitude to be detected (above the limit of
detection (LOD)/limit of quantitation (LOQ) for each compound) via a gas
chromatography (GC) methodology, outlined below, in the following tissues: blood,
brain, diaphragm, liver, lung and skeletal muscle. The animals were starved overnight
(12hr) prior to dosing, then received a combined oral administration, using a gavage
needle of one of the following treatments: 50/1.0/1.0, 75/2.0/2.0, or 100/3.0/3.0
mg/kg of chlorpyrifos/methyl parathion/parathion. Corn oil was used as the vehicle.
Following exposure, the animals were euthanized (stunning followed by decapitation)
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at 3 time points (1hr, 4hr, 24hr) with one animal/time point/dosage combination.
Brain, diaphragm, lung, liver and skeletal muscle were dissected out. The blood was
collected and separated into serum and erythrocytes. Four hundred microliters of an
acetic acid solution (2.5M) saturated with sodium chloride was added to halt
metabolism and aid in the extraction process (Brzak et al., 1998).
An up-and-down approach was used for the optimization/pilot study. Initially,
the highest 3 doses with 1 animal per time point was tested, and the animals observed
closely for any signs of hypercholinergic activity. If there were no adverse signs, the
tissues indicated were tested for the presence of the OP compounds and their
respective metabolites. If the concentrations were within the range of analyte
detectability then these dosages were used for the formal validation experiments. If
the analytes could not be detected, the dosages were increased to obtain levels that
yielded analyte detection, while concurrently not yielding overt signs of toxicity. If
the initial dosages yielded toxic signs, then dosages were reduced to levels that did
not yield signs. The dosages ultimately selected did not yield obvious signs of
toxicity, in order to assure that cardiovascular function was not altered significantly,
thus potentially invalidating the PBTK/TD models’ general physiological
assumptions.

Validation Experiments
Following the determination of the optimum dosages from the pilot study, the
validation experiments commenced, which, as stated above, were used to test the
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efficacy of the PBTK/TD model. The optimum dosages for the mixture components
were determined to be 5.0mg/kg of chlorpyrifos, and 1.0mg/kg each of methyl
parathion and parathion. This dosage combination was the lowest tested which
remained above the LOD/LOQ for each compound using the GC methodology
outlined below. However, the % brain AChE inhibition at these dosages was greater
than sought, though no overt signs of toxicity were noted. Therefore, an additional
dosage group was employed. Dosages of 2.5mg/kg of chlorpyrifos, and 0.5 mg/kg
each of methyl parathion and parathion, which resulted in 10-15% brain AChE
inhibition, was used to supplement the data acquired from the 5/ 1/ 1mg/kg dosage
group, since these lower dosages could be assumed not to result in significant
disruption of cardiovascular function.
Four time points of sacrifice were used for both dosage groups, 30min, 4, 12, and
24hr, with three treatment animals/time point/dosage group and two control
animals/dosage group. Following exposure, rats were sacrificed by stunning followed
by decapitation. Brain, diaphragm, liver, lung and skeletal muscle were dissected out
and snap-frozen in liquid nitrogen and stored at -80oC. Blood was collected and
centrifuged at 400g for 5min to obtain the serum, which was also stored at -80oC.

Toxicokinetic Analyses
In order to assess the accuracy of the model’s predictions, analytical methods
to quantify the levels of chlorpyrifos, chlorpyrifos-oxon, methyl parathion, methyl
paraoxon, parathion, paraoxon, TCP, and 4-nitrophenol in the selected tissues, noted
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above, were developed. Tissue homogenates, made in 0.05M Tris-HCl buffer/pH7.4,
of brain (40mg/ml), lung (50mg/ml), diaphragm (75mg/ml), skeletal muscle
(100mg/ml), plasma (1.5ml), and liver (100mg/ml) were used for the extractions.
Extraction of the analytes was by addition of 4ml of ethyl acetate to 3ml of the
homogenate or the plasma followed by mixing on a vortex mixer, with the layers
separated by centrifugation (20min at 1600xg). An aliquot of the extract (3.0ml) was
dried under a gentle stream of nitrogen and the residue resuspended in 100µl of
acetonitrile to place the GC response within the linear range of the calibration curve.
Samples (2µl) were injected into an Agilent Technologies 6890N GC in triplicate,
using an autosampler. Tetrachlorvinphos (TCVP; 30µl) was used as the internal
standard. The GC was equipped with both a nitrogen phosphorus detector (NPD) and
an electron capture detector (ECD). Based on preliminary work during the
optimization-dosage range finding pilot study, both detectors were required in order
to detect all the compounds of interest. Separation using the ECD was achieved with
a Restek RTX® -CL Pesticides column (30m x 0.32mm i.d. x 0.5µm film thickness;
Restek, Bellefonte, PA, USA). Helium was used as the carrier gas, with argon (95%)
and methane (5%) as the makeup gas. For the NPD, a Restek RTX®-5 column (30m
x 0.32mm i.d. x 1.5µm film thickness; Restek, Bellefonte, PA, USA) was used.
Hydrogen was used as the carrier gas and helium as the makeup. The temperature was
ramped at a rate of 15oC/min from 65 to 165 oC, which was held for 2min and then
followed by a second ramp of 50 oC/min to a final temperature of 230oC. The injector
and detector temperatures were set at 275 and 300 oC, respectively. The compounds
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of interest were identified by comparison of retention times with those of authentic
standards. Similarly, the compounds were quantified by comparison with calibration
curves constructed from standards containing a constant amount of TCVP and
varying amounts of the compounds of interest. Calibration standards were prepared
and extracted in parallel with the experimental samples.

Statistical Analysis
Calculation of the mean ± SEM (standard error of the mean) for the
concentration-time profiles was the only formal statistical evaluation of the data
conducted. The approach employed by the vast majority of PBTK/TD modelers,
namely, comparing model output with the experimental observations exclusive of any
formal statistical procedures, was adopted in the current study. Since the output
processes of almost all real-world systems and simulations are non-stationary and
autocorrelated, none of the classical statistical tests are directly applicable. Given that
the PBTK/TD model is only a crude approximation of the real physiological system, a
null hypothesis that the natural system and model are the same is obviously false. The
more apt question that must be answered is whether or not the differences between
the actual biological system and the model are significant enough to affect the
conclusions which are derived from the model. For such conclusions, an “eyeball
approach” is the best available at present, and employed in the current study.
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Results
The majority of the parent compounds, CP-oxon, and both of the detoxication
products (TCP, 4-NP) were extractable/quantifiable from all tissues of interest (blood,
brain, diaphragm, liver, lung and skeletal muscle) with the 5mg/kg of CP and 1mg/kg
of MP and P, respectively, dosage group. MP, P, and their respective oxons were
below limits of quantitation for the lower dosage group (2.5mg/kg (CP), 0.5mg/kg
(MP, P), respectively). The extraction recovery efficiencies and GC retention times
are listed in Table 3.1 and 3.2, respectively. Calibration curves of peak area ratios of
all compounds and the internal standard were linear (r2 ranged from 0.9232 to
0.9840).
Concentration of analytes for CP followed the order TCP>>CP>>CPXN in all
tissues (Figures 3.1-3.6). Concentration of analytes for MP and for P followed the
order 4-NP>>MP or P in all tissues (Figures 3.1-3.6). The respective oxons of MP
and P were below the limits of quantitation for both dosage groups. A general trend in
the concentration of all the compounds quantified in tissues was: liver > blood > brain
> lung > diaphragm > skeletal muscle. The data suggest that all three compounds are
rapidly absorbed and metabolized. Peak CP concentrations were attained by 4hr, with
the exception of the liver, with a peak occurrence at 30min. Peak concentrations of
MP were attained by 30min in all tissues. Peak P concentrations were attained by
12hr, with the exception of the liver, 30min. The toxicokinetics of the individual
compounds were not altered by the presence of the others; i.e. peak concentrations of
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CP (4hr), MP (30min), P (12hr) would be expected for an individual exposure to the
respective compounds. This is further confirmed by the PBTK/TD model’s accurate
simulation of these data. With respect to CP-oxon, when detected, the levels generally
agreed quite well with the AChE inhibition pattern in the target tissues, i.e., the
greater the amount of oxon present, the greater the inhibition of AChE observed
(Chapter IV). Furthermore, the overall higher levels of CP present in the tissues, as
compared to both MP and P, link the dominant trend of maximal ChE inhibition (4hr,
Chapter IV) with that of the CP toxicokinetics.
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Figure 3.1. Concentration-time profiles of chlorpyrifos (CP), chlorpyrifos oxon
(CPXN), 3,5,6-trichloro-2-pyridinol (TCP), methyl parathion (MP),
parathion (P), 4-nitrophenol (4-NP) in blood following exposure to a
mixture of 5, 1, 1mg/kg of CP, MP and P, respectively. Experimental
data (symbols), means ± SEM (n = 3) and simulations (lines).
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Figure 3.2. Concentration-time profiles of chlorpyrifos (CP), 3,5,6-trichloro-2pyridinol (TCP), methyl parathion (MP), parathion (P), 4-nitrophenol (4NP) in brain following exposure to a mixture of 5, 1, 1mg/kg of CP, MP
and P, respectively. Experimental data (symbols), means ± SEM (n = 3)
and simulations (lines).
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Figure 3.3. Concentration-time profiles of chlorpyrifos (CP), 3,5,6-trichloro-2pyridinol (TCP), methyl parathion (MP), parathion (P), 4-nitrophenol (4NP) in diaphragm following exposure to a mixture of 5, 1, 1mg/kg of
CP, MP and P, respectively. Experimental data (symbols), means ±
SEM (n = 3) and simulations (lines).
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Figure 3.4. Concentration-time profiles of chlorpyrifos (CP), chlorpyrifos oxon
(CPXN), 3,5,6-trichloro-2-pyridinol (TCP), methyl parathion (MP),
parathion (P), 4-nitrophenol (4-NP) in liver following exposure to a
mixture of 5, 1, 1mg/kg of CP, MP and P, respectively. Experimental
data (symbols), means ± SEM (n = 3) and simulations (lines).
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Figure 3.5. Concentration-time profiles of chlorpyrifos (CP), 3,5,6-trichloro-2pyridinol (TCP), methyl parathion (MP), parathion (P), 4-nitrophenol (4NP) in lung following exposure to a mixture of 5, 1, 1mg/kg of CP, MP
and P, respectively. Experimental data (symbols), means ± SEM (n = 3)
and simulations (lines).
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Figure 3.6. Concentration-time profiles of chlorpyrifos (CP), 3,5,6-trichloro-2pyridinol (TCP), 4-nitrophenol (4-NP) in skeletal muscle following
exposure to a mixture of 5, 1, 1mg/kg of CP, MP and P, respectively.
Experimental data (symbols), means ± SEM (n = 3) and simulations
(lines).
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Discussion
The toxicokinetics of CP, MP, P, CP-oxon, and the detoxication products
(TCP, 4-NP) were quantified in the tissues of interest (blood, brain, diaphragm, liver,
lung and skeletal muscle) with the 5mg/kg of CP and 1mg/kg of MP and P,
respectively, dosage group. MP, P, and their respective oxons were below the limits
of quantitation for the lower dosage group (2.5mg/kg (CP), 0.5mg/kg (MP,P,
respectively)), as were the oxons of both MP and P for the higher dosage group. MP,
P, and their respective oxons were below the limits of quantitation at these dosages
likely because they are efficiently extracted by the liver and metabolized
(deactivated) rapidly. The toxicokinetics of CP-oxon were only sufficiently
characterized in the blood and liver samples. Levels of the 3 oxons in other tissues
were well below the limits of quantitation, likely due to the chemical instability and
reactivity of the oxons, and/or the limited amount formed at the low dosages used in
the present study.
The occurrence of peak levels of MP at the 30min time point in all tissues
suggests that MP is rapidly absorbed and distributed. Protein binding in the blood can
be assumed to play a significant role in the case of CP and P, however, since their
toxicokinetic profiles illustrate their presence in blood for extended periods of time,
as compared to MP. Future studies may benefit from examining earlier time points in
order to better characterize the toxicokinetics of MP. Furthermore, additional time
points between 30min and 12hr would also be of value in order to more closely
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examine the concentration intersections of the compounds at these points, and their
relation to the resulting ChE inhibition described in Chapter IV. It is unfortunate that
the toxicokinetics of the oxons were difficult to characterize; although it was feasible
to identify CP-oxon in the blood and liver, the observed results were very close to the
analytical limits of quantitation. The oxons (all three) were readily quantifiable at the
higher dosages used in the pilot studies; however, at such dosages the animals either
died or displayed significant “cholinergic crisis” signs, making such dosages
inadequate for any meaningful validation studies to be used for the PBTK/TD model.
The limited number of quantifiable oxon samples thus made it particularly difficult to
adequately model the oxon toxicokinetics. However, over the higher dosage range
evaluated, the model predictions and measured concentrations were reasonably
comparable given the limitations of the data.
As will be shown in the following chapter (IV), the model was able to
accurately predict ChE inhibition quite well, even though the oxon toxicokinetic data
were limited in the present study. The presence of the parent compounds, specifically
their time of maximal concentration, in the selected tissues appears to be a good
predictor of ChE inhibition. It should be kept in mind that mere concentration of the
various compounds is but one factor in the determination of the magnitude and extent
of ChE inhibition in the target and non-target tissues.
The detoxication products, 4-NP and TCP, were detected in all target tissues
as well as in liver and plasma. Given that 4-NP and TCP were detected more readily
than the parent compounds indicates that metabolism, and perhaps esterase
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phosphorylation, occurred quite readily. Brain, diaphragm, and lungs showed
significant levels of 4-NP and TCP, as compared to the parent compounds, suggesting
that these tissues are likely active in extrahepatic metabolism; some of this may have
resulted from phosphorylation of serine esterases, and dearylation as well.
Extrahepatic metabolism of the parent compounds in the mixture, whether activation
or detoxication, may have significant impact in acute exposures to OP insecticides.
Hence, metabolic activity of target sites, particularly peripheral target sites such as
brain, diaphragm, lungs, etc., may be a critical factor in determining acute toxicity
levels. Chronic toxicity also may depend on target site metabolic activities, especially
since occupational exposures are repetitive and cumulative in nature, and moreover
since OP insecticides, in the prototypical dermal or respiratory exposure routes may
circumvent the liver. Although chronic toxicity was not investigated in the present
study per se, the current PBTK/TD model has the flexibility to explore such
scenarios; which are otherwise difficult or unethical to test in real-life.
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TABLE 3.1
Extraction Recovery Efficiencies
_____________________________________________________________________
Percent Recovery of Compounds
_____________________________________________________________________
Tissue
CP
CPXN TCP
MP
MPXN
P
PX
4-NP
Brain
87.93
79.50 82.75
84.92 72.31
78.19 73.89
82.99
(5.44) (2.84) (8.68) (7.99) (8.97) (6.10) (11.56) (5.04)
Blood
74.83
76.66 76.11
88.30 75.89
71.00 83.92
86.52
(3.97) (6.41) (8.53) (2.99) (12.01) (8.17) (3.59)
(3.22)
Diaphragm
78.38
75.00 69.32
71.88 73.12
74.50 72.49
81.89
(6.10) (5.88) (10.92) (9.84) (9.31) (6.44) (7.78)
(5.29)
Lung
79.72
74.59 77.92
76.92 68.91
67.93 75.89
77.12
(12.42) (5.98) (5.56) (3.82) (7.66) (5.92) (9.31)
(10.02)
Liver
89.47
67.31 83.59
66.79 69.33
77.92 68.29
84.43
(3.81) (8.68) (3.58) (5.51) (2.99) (5.90) (12.94) (6.62)
Skeletal Muscle 75.83
73.22 77.53
69.40 72.63
66.08 69.23
82.61
(10.62) (9.83) (6.31) (7.84) (3.90) (4.79) (9.01)
(8.17)

Each value represents the mean (±SEM) of 3 determinations. Chlorpyrifos (CP),
chlorpyrifos oxon (CPXN), 3,5,6-trichloro-2-pyridinol (TCP), methyl parathion (MP),
methyl paraoxon (MPXN), parathion (P), paraoxon (PXN), 4-nitrophenol (4-NP).

50

TABLE 3.2
Retention Times of Compounds

_____________________________________________________________________
Retention Time (min)
Compound
ECD
NPD
_____________________________________________________________________
Chlorpyrifos

14.13 (±0.05)

18.52 (±0.05)

Chlorpyrifos oxon

8.02 (±0.05)

18.36 (±0.05)

Methyl parathion

14.26 (±0.05)

15.51 (±0.05)

Methyl paraoxon

8.32 (±0.05)

13.33 (±0.05)

Parathion

14.97 (±0.05)

18.58 (±0.05)

Paraoxon

14.86 (±0.05)

16.54 (±0.05)

8.06 (±0.05)

6.14 (±0.05)

10.28 (±0.05)

10.73 (±0.05)

TCP
4-nitrophenol
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CHAPTER IV
MODEL VALIDATION: TOXICODYNAMIC ANALYSES

Introduction
The Food Quality Protection Act of 1996 mandates that all pesticides acting
through a common mechanism of toxicity undergo cumulative risk assessments. The
primary concern is that exposure to multiple members of a common-mechanism
group might pose a health risk even if the individual components of the mixture are
present at levels below their respective no-observed-adverse-effect levels. OP
insecticides were the first class of chemicals to undergo a cumulative risk assessment
(US EPA, 2002). As such, they share a common mechanism of toxicity, the inhibition
of AChE, resulting in accumulation of acetylcholine in cholinergic synapses and
excessive stimulation of cholinergic pathways in central and peripheral nervous
tissues.
The potential toxicity of an OP insecticide mixture is dependent upon a
combination of the amount delivered to the target systems and the balance between
activation and detoxication. Many OP insecticides, including the ones in the present
study, are phosphorothionates (possessing a P=S group) and are weak
anticholinesterases; they must be bioactivated by CYP450 to their oxon metabolites
(possessing a P=O group) which are potent anticholinesterases. The oxons can inhibit
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a variety of serine esterases including AChE in target tissues, i.e., brain, as well as
non-target esterases (carboxylesterases), in non-target tissues, i.e. blood and liver.
The inhibition of non-target esterases stoichiometrically destroys oxon molecules and
is an effective form of protection of the target, brain AChE, from inhibition.
As acknowledged in Chapter I, limited experimental data are available on the
effects (esterase inhibition) of mixtures of OP insecticides; such information would
be of great value in cumulative risk assessments. The toxicodynamic analyses of the
present study were designed with the following objective: to perform in vivo
experiments to quantitate the inhibition of AChE and CbxE following exposure to a
ternary OP insecticide mixture; composed of chlorpyrifos, methyl parathion and
parathion. These data were used to validate the PBTK/TD model simulations.

Materials and Methods

Chemicals
Analytical grade chlorpyrifos, chlorpyrifos-oxon, methyl parathion, methyl
paraoxon, parathion, paraoxon, 4-nitrophenol, TCP, and 4-nitrophenyl valerate were
provided by Dr. Howard W. Chambers, Department of Entomology and Plant
Pathology, Mississippi State University, and were synthesized as previously
described (Chambers et al., 1990). Analytical grade parathion and methyl parathion
were re-crystallized from a generous gift from Monsanto Company (St. Louis, MO).
Analytical grade chlorpyrifos and 3,5,6-trichloro-2-pyridinol, for synthesis of
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chlorpyrifos-oxon, were a generous gift from DowElanco Chemical (Indianapolis,
IN). The same batch of chemicals was used throughout the study. All other
biochemicals were purchased from Sigma Chemical Co. (St. Louis, MO).

Animals and Treatments
Adult male Sprague-Dawley rats [Crl:CD(SD)BR] (280-330g) were obtained
from Charles River Laboratories, Inc. Animals were housed in an AAALAC
accredited facility and maintained in a temperature controlled room (22 ± 1)oC, 12:12
hour light/dark cycle, with food and water available ad libitum. Prior to dosing, food
was withheld overnight (12hr) to allow for gastric emptying, to minimize the
adsorption of the mixture components by stomach contents following oral gavage
administration. The Mississippi State University Animal Care and Use Committee
approved all procedures.

Acetylcholinesterase Assay
The tissues used for this component were isolated along with the tissue
samples used for the toxicokinetic analyses (Chapter III). Frozen samples of brain,
diaphragm, lung, and skeletal muscle were assayed using an established technique in
our lab (Ellman et al., 1961; as modified in Chambers and Chambers, 1989) to
determine the amount of cholinesterase activity. Tissues were homogenized in 0.05M
Tris-HCl (pH 7.4, 25°C): brain 40mg/ml, lung 200mg/ml, diaphragm 100mg/ml, and
skeletal muscle 100mg/ml. The chromagen, 0.024M 5,5-dithio-bis(2-nitrobenzoic
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acid) (DTNB) and the substrate, 0.1M acetylthiocholine (ATCH) were mixed in a
ratio of 2:1 and diluted 1:10 with warm 0.05M Tris-HCl. In a microplate, 155µl of
warm Tris-HCl and 18.75µl of the diluted DTNB/ATCH mixture were added into
eight wells. Into three wells, 10µl of 0.01M eserine sulfate was added to correct for
non-ChE hydrolysis of the substrate. The reaction was initiated by addition of 25µl of
the homogenate to all eight wells. Using a Phenix Sunrise® plate reader, readings
were taken every 5sec for 5min. The average slope of the three eserine sulfate blanks
were subtracted from the average slope of the five sample wells. This corrected slope
was used to calculate specific activity. Employing the same method, 10µl of
undiluted serum per well was used to determine the serum ChE activity.
Diaphragm, lung, and skeletal muscle homogenates were filtered through
polyester fiberfill twice to remove large particulates. The ChE activity was
determined by adding 100µl of DTNB, 30µl of ATCH, 1.8ml of 0.05 Tris-HCl, and
100µl of homogenate into a cuvette and placed into a Perkin-Elmer Lambda 25
spectrophotometer. Readings were taken every 5sec for 2min. To correct for
particulates settling during the assay and causing reading errors, the average slope
between 25sec and 2min was used to calculate specific activity.

Carboxylesterase Assay
For the carboxylesterase (CbxE) analyses, liver and plasma samples were
assayed spectrophotometrically using 4-nitrophenyl valerate as the substrate
(Chambers et al., 1990). Serum was diluted 1:19 with 0.05M Tris-HCl and liver was
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homogenized 5mg/ml with 0.05 Tris-HCl. Diluted serum and homogenized liver
(40µl) samples were added to each of six test tubes containing 1.8ml of cold Tris-HCl
buffer. Paraoxon (20µl of 0.1M solution) was added to the last two of each set to
completely inhibit the CbxE activity and correct for non-CbxE hydrolysis of
substrate. After incubating in a warm, shaking waterbath for 10min, 20µl of
nitrophenyl valerate was added and incubated for 5min. The reaction was terminated
by addition of 0.5ml of 2% Tris-SDS and each sample was read
spectrophotometrically at 405nm. The average of the two paraoxon blanks was
subtracted from the average of the remaining four tubes.

Protein Quantification
Protein concentrations for all of the tissues were determined by the method of
Lowry et al. (1951). The serum was diluted 1:19, diaphragm 1:5, lung 1:4, and
skeletal muscle 1:4 with 0.05M Tris-HCl to give absorbance readings in the linear
range of the 50µg and 200µg standards. Brain and liver were not diluted. The protein
concentrations were used to calculate AChE and CbxE specific activity as nmoles
product min-1 mg protein-1.

Statistical Analysis
Calculation of the mean ± SEM (standard error of the mean) for the AChE and
CbxE percent inhibition-time profiles was the only formal statistical evaluation of the
data conducted. The approach employed by the vast majority of PBTK/TD modelers,
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namely, comparing model output with the experimental observations exclusive of any
formal statistical procedures, was adopted in the current study. Since the output
processes of almost all real-world systems and simulations are non-stationary and
autocorrelated, none of the classical statistical tests are directly applicable. Given that
the PBTK/TD model is only a crude approximation of the real physiological system, a
null hypothesis that the natural system and model are the same is clearly false. The
more apt question posed is whether or not the differences between the biological
system and the model are significant enough to affect the conclusions which are
derived from the model. For such conclusions, an “eyeball approach” is the best
available at present.

Results
The results of the present study demonstrate a clear dose- and time-dependent
inhibition of tissue ChE activity. The extent of in vivo tissue sensitivity followed the
order: serum > liver > lung > diaphragm > brain > skeletal muscle. Following
exposure to both dosages of the mixture, AChE activity was rapidly inhibited by
30min and reached maximal inhibition by 4hr in all tissues (Figures 4.1, 4.2, 4.4, 4.8,
4.9, 4.11), with the exception of muscle and serum, maximal inhibition occurred at
12hr (Figures 4.5, 4.6, 4.12, 4.14). Liver and serum CbxE maximal inhibition was
present by 4hr for both dosage groups (Figures 4.3, 4.7, 4.10, 4.13). Cholinesterase
inhibition in the tissues ranged from 11- 37% for the lower dosage, and 29-93% for
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the higher dosage group; with few exceptions, inhibition was generally additive and
was supported by the model simulations.
The percent activity of AChE and CbxE following exposure to both dosage
groups was significantly different from control at 30min through 24hr. Very little to
slow recovery of AChE and CbxE activity was seen in the tissues from the 12hr –
24hr time points, following the window of maximal inhibition within the tissues (4hr
-12hr); i.e. enzyme activity did not return to control levels through 24hr post-dosing.
As mentioned above, inhibition was generally additive at most time points and in
most tissues with the lower dosage group. However, with the higher dosage group,
deviations from additivity were seen particularly in the diaphragm and lung (Figures
4.9, 4.11). In these instances, the model overestimated the percent inhibition at the
early time points, 30min – 4hr and underestimated the percent ChE inhibition at 24hr,
in the case of the diaphragm. In addition, the model overestimated at 4hr and
underestimated at 12hr CbxE inhibition in the serum (Figure 4.7, 4.13) for both
dosage groups. The model was not able to accurately simulate muscle AChE
inhibition following exposure to both dosage groups, the experimental data, however,
are shown in Figures 4.5, 4.12. With that said, the experimental data did follow the
basic trend of the model simulations, however; accurately predicting the time point of
maximal inhibition, and model fits were 80% or greater for any particular data set.

58

Brain
100
90

% of Control

80
70
60
50
40
30
20
10
0
0

4

8

12

16

20

24

Time (hr)

Figure 4.1. Time-course of inhibition of brain cholinesterase activity in adult male
rats following exposure to 2.5, 0.5, 0.5mg/kg of chlorpyrifos, methyl
parathion and parathion respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.2. Time-course of inhibition of diaphragm cholinesterase activity in adult
male rats following exposure to 2.5, 0.5, 0.5mg/kg of chlorpyrifos,
methyl parathion and parathion, respectively. Experimental data
(symbols), means ± SEM (n = 3) and simulations (lines).
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Figure 4.3. Time-course of inhibition of liver carboxylesterase activity in adult male
rats following exposure to 2.5, 0.5, 0.5mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.4. Time-course of inhibition of lung cholinesterase activity in adult male
rats following exposure to 2.5, 0.5, 0.5mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.5. Time-course of inhibition of skeletal muscle cholinesterase activity in
adult male rats following exposure to 2.5, 0.5, 0.5mg/kg of chlorpyrifos,
methyl parathion and parathion, respectively. Experimental data
(symbols), means ± SEM (n = 3).
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Figure 4.6. Time-course of inhibition of serum cholinesterase activity in adult male
rats following exposure to 2.5, 0.5, 0.5mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.7. Time-course of inhibition of serum carboxylesterase inhibition in adult
male rats following exposure to 2.5, 0.5, 0.5mg/kg of chlorpyrifos,
methyl parathion and parathion, respectively. Experimental data
(symbols), means ± SEM (n = 3) and simulations (lines).

65

Brain
100
90

% of Control

80
70
60
50
40
30
20
10
0
0

4

8

12

16

20

24

Time (hr)

Figure 4.8. Time-course of inhibition of brain cholinesterase activity in adult male
rats following exposure to 5, 1, 1mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.9. Time-course of inhibition of diaphragm cholinesterase activity in adult
male rats following exposure to 5, 1, 1mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.10. Time-course of inhibition of liver carboxylesterase activity in adult
male rats following exposure to 5, 1, 1mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.11. Time-course of inhibition of lung cholinesterase activity in adult male
rats following exposure to 5, 1, 1mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.12. Time-course of inhibition of skeletal muscle cholinesterase activity in
adult male rats following exposure to 5, 1, 1mg/kg of chlorpyrifos,
methyl parathion and parathion, respectively. Experimental data
(symbols), means ± SEM (n = 3).
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Figure 4.13. Time-course of inhibition of serum carboxylesterase activity in adult
male rats following exposure to 5, 1, 1mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Figure 4.14. Time-course of inhibition of serum cholinesterase activity in adult male
rats following exposure to 5, 1, 1mg/kg of chlorpyrifos, methyl
parathion and parathion, respectively. Experimental data (symbols),
means ± SEM (n = 3) and simulations (lines).
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Discussion
The pattern of AChE and CbxE inhibition appears to be largely dominated by
CP, which agrees well with the toxicokinetic data presented in Chapter III. It can be
inferred that both MP and P are contributing to the rapid inhibition seen at 30min and
responsible for the extended inhibition and slow recovery evident from 12hr-24hr
time points. The “protective enzymes” within the body are serum ChE and CbxE, and
liver CbxE. Inhibition of these protective enzymes leads to a greater amount of the
mixture of parent compounds and/or their respective oxons from being able to reach
target tissues and inhibit AChE. With the higher dosage group, these protective
esterases are significantly inhibited, as shown in Figures 4.10, 4.13, 4.14. Slightly
higher dosages, compared to those used in the current study, would be expected to
lead to saturation of these protective enzymes and potentially lead to greater
inhibition than expected, since more oxon molecules would potentially be available to
inhibit target tissue AChE. However, it has been suggested that only a minimal
amount of AChE is required to maintain normal physiological function, i.e.,
homeostasis (Ellin, 1982).
There appear to be some antagonistic effects among the compounds; there
were less-than-additive effects present in the diaphragm and lung at the higher dosage
exposure. However, since the experimental data for the pattern of brain AChE
inhibition was shown to agree well with the model simulations, it can be assumed that
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metabolism of the compounds in the liver was occurring at a normal rate. Thus, the
interaction may be at the level of distribution, or at the level of the target site itself.
The pattern of inhibition in the diaphragm and lung is not similar to that of serum
AChE inhibition, which implies that serum AChE is not contributing to this pattern in
any significant fashion.
Although the model could not adequately simulate skeletal muscle per se (this
tissue was modeled as a lumped-compartment), the experimental inhibition data
appear to reflect the smaller amount of blood flow, and less delivery of active
metabolites as compared to some of the more well-perfused tissues in the model. The
amount of inhibition was small and relatively inconsequential (Figures 4.5, 4.12) at
the dosage levels used in the current study. The limited blood flow to skeletal muscle
likely explains the shift of maximal AChE inhibition to 12hr, as compared to 4hr for
the other tissues.
The determining factor for how an OP insecticide mixture will react within the
body varies with tissue and time of sampling. As mentioned above, there appears in
some instances to be an interaction, i.e., antagonism, among the compounds in the
diaphragm and the lung. This interaction may be occurring at either the level of
metabolic activation in the liver, the distribution of the compounds to the tissue(s),
interaction with non-target esterases, interaction with the target site, or a combination
of the above. However, the results presented here demonstrate that the ability of the
active metabolite of each compound to inhibit serum ChE and/or serum and liver
CbxE plays an important role in the degree/pattern of ChE inhibition following
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exposure to an OP mixture. The model and experimental results highlight the
protective role of CbxE (inhibition was 70-90 % in the liver and serum, while the
inhibition of brain AChE activity was 15-30 %). The inhibition of liver CbxE by the
individual compounds is reflective of the in vitro potency of the active metabolites of
the three OP insecticides. CP-oxon is a much better inhibitor of CbxE than either MPoxon or P-oxon, and the results of the mixture followed a pattern of inhibition similar
to that of CP alone. Regarding serum CbxE, however, the inhibition by the individual
compounds was not reflective of the in vitro potency of the active metabolites of the
three OP insecticides. Experimentally, exposure to the mixture did not follow the
pattern of inhibition predicted by the model; instead CbxE inhibition appeared to be
dominated by P-oxon and/or an interaction with CP-oxon that resulted in delayed
maximal inhibition, as compared to the effects predicted by the compounds alone. Ma
and Chambers (1994) have reported that P is activated more efficiently than is CP,
while CP is detoxified more efficiently than P. CP-oxon is also a much more potent
inhibitor of CbxE than is P-oxon (Chambers et al., 1990). Theoretically, this higher
affinity of CP-oxon for CbxE would lead to greater non-specific binding by CP-oxon
compared to P-oxon, thus decreasing the amount of CP-oxon that would be available
to reach the target enzyme. Additionally, the higher lipophilicity of CP compared to P
could lead to CP being sequestered by some tissues (Chambers and Carr, 1993).
Sequestrations would decrease the bioavailability of CP, thereby reducing the
immediate impact of the compound on target tissues. This reduction may play a role
in the lower LD50 of P as compared to CP.
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There is comparatively very little detoxication potential in the brain; the
potential variable rates of detoxication among the compounds that are very likely in
blood, are not likely to confound experimental data/model simulation interpretation in
other tissues. Experimental data/ model simulation agreement in serum are much less
consistent presumably because of the presence of additional detoxication
mechanisms, such as CbxE and BuCh. Differences in the pattern of inhibition in the
mixture as compared to that of the individual compounds, may be partially the result
of competition for P450-meditated bioactivation. The patterns may also be due to
different affinities of the oxons for AChE and CbxE. The model fit for serum CbxE to
the experimental data could not be improved by adjusting the parameters associated
with CbxE reactivation, aging, or degradation. Optimization of the rate constants (Ki)
for CP-oxon and P-oxon resulted in a somewhat better fit, but failed to fully reconcile
the differences between the predicted percent peak inhibition (4hr) and the
experimentally determined percent peak inhibition (12hr). Model parameters,
metabolic constants Vmax and Km, and binding/dissociation constants of free/bound
AChE for the mixture were reevaluated and the fit was only minimally improved. The
serum concentrations were only secondarily influenced by Vmax and Km. With
values giving the smallest bile residuals, a significant change in the fit for serum
concentrations could only be obtained by changes to other parameters, notably protein
binding ratios. Aside from the discrepancies observed with the serum, very little
model “fitting” (i.e., finding a mathematical equation and a set of parameter values

76

such that the values predicted by the model are close to the observed experimental
values) was required.
In toxicokinetic interactions, the presence of a second or third chemical alters
the kinetics such that a unit of administered dose no longer produces a unit of dose at
the target tissue. In toxicodynamic interactions, the presence of other compounds
alters the dynamics such that a unit tissue dose no longer produces a unit of response.
B-EST (i.e., AChE, BuChE, and CbxE) inhibition is an integrated function of targettissue dosimetry, esterase affinity for the oxon, and the number of available esterase
binding sites in each tissue compartment. In this regard, improvements in the
predictive capability of the current model could be obtained with data that better
characterize the time-course of specific esterase activities in blood over a broad range
of compound exposure.
A particular concern in mammals is exposure to lipophilic compounds, such
as CP. Following exposure of P, for example, in rats, if mortality does not occur
within 24-48hr, the rat will generally survive. However, it has been demonstrated that
high-dosage acute exposures to CP can produce mortality 4 days post-exposure
(Chambers and Carr 1993). With chronic exposures, the body compensates for
chronic inhibition of AChE by reduction of ACh receptor number, which reduces the
impact of high levels of ACh in the synapse. Generally, down-regulation of receptor
numbers does not occur following an acute exposure. Description of such dynamic
processes would be valuable to include in future PBTK/TD models to expand their
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use for chronic exposure conditions. However, problems with properly describing
such dynamic processes exist, as will be discussed in Chapter V.
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CHAPTER V
GENERAL CONCLUSIONS

The PBTK/TD model in the present study was developed, using a framework
from published individual PBTK/TD models, as a quantitative tool for assessing OP
insecticide dosimetry and cholinesterase inhibition in rats. The PBTK/TD modeling
approaches used in the current study are ideally suited for assessing dosimetry and
biological responses following exposures to OP insecticide mixtures, and for
development of “family models” that can be used for related compounds and/or
metabolites. Overall, the PBTK/TD model successfully predicts dosimetry and
cholinesterase inhibition in the selected tissues. The present study demonstrates the
utility of using previously developed individual models and in vitro/in vivo data from
the open literature to construct a reliable mixture model. Cholinesterase inhibition in
selected tissues peaked at 4hr, ranged from 11- 37% for the lower dosage group, and
29-93% for the higher dosage group, and was generally additive; the overall mixture
response appeared driven by CP. Model predictions diverged from the experimental
data for serum, but for other tissues there was good agreement. The model is used to
describe a complex set of multivariate data; hence it is not surprising that some overand underestimation occurred. The model fit for the experimental data is quite good,
considering the diverse sources of data used in the creation of the model; the shapes
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of the predicted curves are generally accurate. The assumption of response additivity
holds for low dosage exposures, which are likely to be encountered in
environmental/occupational settings. An assumption of additivity at higher dosages
than those used in the current study may not be appropriate in all tissues, particularly
those tissues involved in maintaining respiratory function. This is likely only a
concern in those instances of occupational accidents or other such nontypical/extreme exposure scenarios. Model development is an iterative process; the
model is improved/revised as more data become available. Therefore, the model is
not “complete” per se; it can be improved upon as more data are acquired. The model
is sufficiently flexible that a similar approach could be readily applied to other
multiple combinations of OP insecticides, provided necessary data are available in the
literature and/or through focused experimental studies, to address the impact of
variable OP exposure scenarios and the impact of sensitive sub-populations for the
risk assessment of OP insecticides.
OP insecticides commonly co-occur in the environment, which can potentially
lead to antagonistic, additive, or synergistic neurotoxicity. When considering
combined action of chemicals at low dosages, one is left to contemplate if real
“interactions” are likely to occur. There is little uncertainty that the combined toxic
action of compounds is a dose-dependent phenomenon. At low doses,
physicochemical interactions are of relatively little importance and toxicokinetic and
toxicodynamic interactions may be atypical. At very low doses, even receptor
occupancy and competition for receptors may be of little importance. Therefore,
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interactions such as potentiation or antagonism may not be very relevant in the lowdose region. This study indicates that the joint toxicity of anticholinesterase mixtures
can be accurately predicted from the knowledge of individual chemicals within a
mixture; OP insecticides are non-interactive in terms of AChE inhibition, and it is
possible to estimate the cumulative neurotoxicity of mixtures by response addition, at
least at low dosage exposure levels.
The primary function of PBTK/TD models is prediction of
concentrations/effects of various environmental toxicants, and/or their metabolites in
different organ systems. However, most such models view physiological systems as
static, unable to respond to physiological changes/insults (Clewell et al., 2003;
Krishnan et al., 2001; Welling, 1996). This assumption of “static” physiological
systems is not realistic for chemicals that are stressors, especially neurotoxic
chemicals such as OP insecticides. Some recent attempts have been made to include
physiological changes in PBTK/TD models, these efforts however do not integrate
the changes directly into the modeling process; they provide fixed time-dependent
functions which have extremely limited applicability to very narrow dosing regimens
(Lu et al., 2006). By using integral or delay terms in modeling approaches, it may be
possible to model/account for more complex reactant physiological behavior; i.e.,
changes in cardiac output. Such approaches, however, are beyond the scope of the
current study. While the current model has adjustable parameters to allow fitting to
experimental data, the degree of adjustment is often limited by physical and
biological considerations. The difficulty produced by this circumstance is, in fact, one
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of the advantages of modeling; a purely empirical fit would not illuminate internal
inconsistencies in the experimental data. In many instances, the modeler is restrained
by his scientific principles from assigning values to critical coefficients, and this
restraint may ultimately lead to a better understanding and description of the mixture
metabolic processes.
Although the current PBTK/TD model successfully describes the
toxicokinetics and toxicodynamics of the compounds over the dosages used, it is
important to recognize that even the low dosages evaluated in the current study are
still significantly greater than typical aggregate (total dietary and residential) human
exposures. For example, in both adults and children, potential nonoccupational
aggregate exposures to CP are estimated to range from 0.0002 mg/kg-day (adults) to
0.0005 mg/kg-day (infants and small children) (Cochran, 2002), which is many-fold
below the lowest dosage (0.5mg/kg) used in the present study. Based upon the
observed dose response, where the parent compounds and oxons were nondetectable
and ChE activity was minimally depressed at the lower dosage, it is hypothesized that
a significant first-pass metabolism, would be observed at environmentally relevant
doses. In this regard, a number of recent studies have demonstrated that intestinal
epithelial cells have CYP metabolic capacity and are capable of significantly altering
oral bioavailability of drugs and chemicals in animals and humans (Obach et al.,
2001; Paine et al., 1999; Zhang, et al., 1999). A number of CYP isoforms residing
within the intestine have been shown to metabolize many OP insecticides, including
chlorpyrifos and parathion (Butler and Murphy, 1997; Fabrizi et al., 1999; Sams et
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al., 2000). In addition, P-glycoproteins (multidrug resistance proteins) are located in
the apical borders of intestinal cells, and are known to be up-regulated and bound by
CP-oxon (Lanning et al., 1996). Thus, an unknown amount of first-pass detoxication
and activation could occur in the intestines, and oxon that is generated in enterocytes
would be subject to removal by P-glycoproteins. Since the current model does not
incorporate intestinal metabolism or P-glycoprotein removal of oxon, it is probable
that the model overestimates low-dose oral bioavailability, thereby potentially
overestimating dosimetry and dynamic response. This presumed overestimation in
fact was evident in some tissues in the present study at both the toxicokinetic and
toxicodynamic levels.
The current PBTK/TD model can function as a constructive tool for helping
design and focus future experimental research. The capacity of the model to
accurately predict dosimetry and response is limited by the adequacy of the model
parameters and limitations of experimental data. As with all models, developing and
validating a PBTK/TD model is an iterative process and highlights existing confines
of understanding of critical biological processes that help identify important data
gaps. In the process of refining the model to fit the data, several key model
parameters that impact the model fit to data sets were noted. The parameter with the
strongest consequence to data fit was plasma protein binding to the compounds and,
to a slightly lesser extent, the oxons. Improved parameter estimates for the inhibition
of oxons with B-EST, and in particular CbxE tissue inhibition kinetic parameters
would be helpful in the future. Although the formation of oxons can be inferred from
83

the inhibition of ChE activities, the amount formed as well as the toxicokinetics had
limited detection at the dosage levels used in the present study. This is primarily a
reflection of the half-life of the compounds; for example, a 60-fold difference exists
between the half-lives of paraoxon and parathion in rats (Eigenberg et al., 1983). In
addition, the oxons are sufficiently reactive that they do not remain stable for any
appreciable length of time. Such factors as the length of time esterases remain
inhibited, the potency of the oxons as anticholinesterases, and the competition of the
compounds for enzymes of metabolism are probably the main contributing factors to
non-additive levels of ChE inhibition. Predicting effects of mixtures in vivo thus
requires knowledge of both activation and detoxication potentials, potencies of the
oxons as ChE and CbxE inhibitors, ability of the oxons to serve as substrates for Aesterases, and time/sequence of exposure to the compounds.
Clearly, it is impossible to conduct all of the necessary laboratory experiments
on toxicant effects, dosages, time frames, and routes of administration, not only for
OP insecticides, but for all environmentally-relevant toxicants. PBTK/TD modeling,
when based on logical approaches and concrete data, can help provide useful
predictions on dosimetry and effects. Occasionally, models must be developed with
an absence of data sets; when this occurs certain assumptions must be made from
similar data or certain simplifications must be used in the model. The endpoint of
easily measured ChE inhibition in the present study does make the modeling of OPmolecular interactions easier compared to the modeling of many toxicants that do not
covalently bind to targets, or that exert as-yet-undefined molecular actions. With any
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modeling exercise, the accuracy of the model is limited by the quality of the data.
When model predictions and data are incompatible, the data can be wrong, the model
can be wrong, or both can be wrong to varying degrees. It is imperative to bear in
mind that PBTK/TD models do not replace well planned experimental studies.
Rather, they are adjuncts which serve to capitalize on the utility of experimental
results, assist in more precise planning of other experiments and help design costeffective studies. As such, they are tools to aid in identifying and hopefully reduce
some of the many uncertainties inherently associated with the risk assessment
process. Ultimately, well-organized assessments based on experimentation,
PBTK/TD modeling, and realistic monitoring and sound scientific judgment will
result in rational and successful risk management decisions. PBTK/TD models offer
promise in understanding and possibly screening for interactive effects of chemical
mixtures; however, a great deal of validation is necessary before they can be applied
to chemical mixture assessments. Instead of “validation”, some in the PBTK/TD
modeling community have recently suggested validation be described instead as
“juxtaposition” of model predictions with the experimental data. This purportedly
treats the experimental data and the model predictions on a more even level; the
debate is primarily one of semantics however. At present, is it questionable if a
computer model can fully represent the complexity of the physiology and interactions
of higher-order chemical mixtures in living biologic systems; the future of in silico
modeling appears bright however, with momentous advances made with each passing
year.
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! OPS.CSL A PHYSIOLOGICALLY-BASED TOXICOKINETIC AND
TOXICODYNAMIC (PBTK/TD) MODEL FOR A TERNARY
ORGANOPHOSPHORUS INSECTICIDE MIXTURE IN RATS
! JULIAN T. PITTMAN
'---------------------------------------------------------------'
PROGRAM SWEEP
INITIAL
L1.CONTINUE
CALL INITD
OPEN(FILE='OUTPUT.DAT')
ALGORITHM IALG=2 $ 'GEAR INTEGRATION ALGORITHM FOR STIFF SYSTEMS'
!-----TIMING COMMANDS-----!
CONSTANT TSTOP=0.5! 4! 12! 24 ! LENGTH OF SIMULATION (H)
CONSTANT POINTS=1000
! NUMBER OF SIMULATED DATA POINTS
CINT=TSTOP/POINTS
! COMMUNICATION INTERVAL (H)
TM=T*60
! HOURS TO MINUTES CONVERSION
TD=T/24
! HOURS TO DAYS CONVERSION
w=t
schedule cat1 .at.tchng
cizone=0!1.0
!-----PHYSIOLOGICAL PARAMETERS-----!
CONSTANT
CONSTANT
CONSTANT
LUNGS
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
BW)
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
BW)
CONSTANT

BW=0.22
QCC=15
QHC=0.25

! BODY WEIGHT (KG)
! CARDIAC OUTPUT (L/H/KG BW)
! PROPORTION OF CARDIAC OUTPUT TO HEART AND

QDC=0.006
QLC=0.25
QBRC=0.03
QFC=0.09
VHC=0.04

! PROPORTION OF CARDIAC OUTPUT TO DIAPHRAGM
! PROPORTION OF CARDIAC OUTPUT TO LIVER
! PROPORTION OF CARDIAC OUTPUT TO BRAIN
! PROPORTION OF CARDIAC OUTPUT TO FAT
! FRACTION HEART AND LUNGS TISSUE VOLUME (L/L

VDC=0.0003
VLC=0.04
VBRC=0.06
VFC=0.07
VAC=.0185

! FRACTION DIAPHRAGM VOLUME (L/L BW)
! FRACTION LIVER TISSUE VOLUME (L/L BW)
! FRACTION BRAIN TISSUE VOLUME (L/L BW)
! FRACTION BODY FAT VOLUME (L/L BW)
! FRACTION POOLED VENOUS BLOOD VOLUME (L/L

VVC=.05555

! FRACTION ATERIAL BLOOD VOLUME (L/L BW)

!-----CHLORPYRIFOS-SPECIFIC PARAMETERS-----!
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CONSTANT
CONSTANT
CONSTANT
CONSTANT
(µM/H/KG
CONSTANT
(µM/L)
CONSTANT
(µM/L)
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT

MW=350.57
! MOLECULAR WEIGHT (G/MOL)
VMAX1=74421!57003 ! LIVER CP450 VMAX1 (µM/H/KG BW)
VMAX2=80!273!0
! LIVER CP450 VMAX2 (µM/H)
VMAX2= 1.8085*vmax1!74421!57003 ! LIVER CP450 VMAX1
BW)
KM1=240
! LIVER CP450 MICHAELIS-MENTON KM1
KM2=250!16.1

! LIVER CP450 MICHAELIS-MENTON KM2

KM2=1.64*km1!16.1
PH=23
!
PD=6
!
PL=22
!
PBR=33
!
PF=435
!
PSK=6
!
PR=10
!
PS=6
!

! LIVER CP450 MICHAELIS-MENTON KM2
HEART AND LUNGS/BLOOD PART. COEF.
DIAPHRAGM/BLOOD PART. COEF.
LIVER/BLOOD PART. COEF.
BRAIN/BLOOD PART. COEF.
FAT/BLOOD PART. COEF.
SKIN/BLOOD PART. COEF.
RICHLY PERFUSED TISSUE/BLOOD PART. COEF.
SLOWLY PERFUSED TISSUE/BLOOD PART. COEF.

!-----CHLORPYRIFOS-OXON-SPECIFIC PARAMETERS-----!
CONSTANT
CONSTANT
CONSTANT
CONSTANT
(µM/L)
CONSTANT
CONSTANT
(µM/L)
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT

MWW=334.5
MWW=190.0
VMAX3=179!273!
KM3=2.86

! MOLECULAR WEIGHT OXON (G/MOL)
! MOLECULAR WEIGHT TCP (G/MOL)
! PLASMA A-ESTERASE VMAX (µM/H/KG BW)
! PLASMA A-ESTERASE MICHAELIS-MENTON KM

VMAX4=179.4
KM4=1.64

! LIVER A-ESTERASE VMAX (µM/H/KG BW)
! LIVER A-ESTERASE MICHAELIS-MENTON KM

PHH=19
PDD=4.9
PLL=17
PBRR=26
PFF=342
PSKK=6
PRR=8.1
PSS=4.9

!
!
!
!
!
!
!
!

HEART/BLOOD PART. COEF.
DIAPHRAGM/BLOOD PART. COEF.
LIVER/BLOOD PART. COEF.
BRAIN/BLOOD PART. COEF.
FAT/BLOOD PART. COEF.
SKIN/BLOOD PART. COEF.
RICHLY PERFUSED TISSUE/BLOOD PART. COEF.
SLOWLY PERFUSED TISSUE/BLOOD PART. COEF.

!-----METHYLPARATHION-SPECIFIC PARAMETERS-----!
CONSTANT MW=263.23
! MOLECULAR WEIGHT (G/MOL)
CONSTANT VMAX1=24.28!29.09
! LIVER CP450 VMAX1 (MG/H/KG BW)
CONSTANT VMAX2=34.29!33.53
! LIVER CP450 VMAX2 (MG/H)
CONSTANT VMAX2= 1.8085*vmax1!35.38!32.96 ! LIVER CP450 VMAX1
(MG/H/KG BW)
CONSTANT KM1=21.64
! LIVER CP450 MICHAELIS-MENTON KM1
(MG/L) CONSTANT KM2=36.385!23.76 ! LIVER CP450 MICHAELIS-MENTON KM2
(MG/H/KG BW)
CONSTANT KM2=2.0384*km1!24.757 ! LIVER CP450 MICHAELIS-MENTON KM2
(MG/H/KG BW)
CONSTANT PH=5
! HEART AND LUNGS/BLOOD PART. COEF.
CONSTANT PD=8
! DIAPHRAGM/BLOOD PART. COEF.
CONSTANT PL=7
! LIVER/BLOOD PART. COEF.
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CONSTANT
CONSTANT
CONSTANT
CONSTANT

PBR=29
PF=80
PR=4
PS=2

!
!
!
!

BRAIN/BLOOD PART. COEF.
FAT/BLOOD PART. COEF.
RICHLY PERFUSED TISSUE/BLOOD PART. COEF.
SLOWLY PERFUSED TISSUE/BLOOD PART. COEF.

!-----METHYLPARAOXON-SPECIFIC PARAMETERS-----!
CONSTANT
CONSTANT
CONSTANT
(MG/L)
CONSTANT
CONSTANT
(MG/L)
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
COEF.
CONSTANT
COEF.

MWW=247.02
! MOLECULAR WEIGHT (G/MOL)
VMAX3=54.93! 65! 102.5!49.30 !PLASMA A-ESTERASE VMAX (MG/H)
KM3=82.49
! PLASMA A-ESTERASE MICHAELIS-MENTON KM
VMAX4=93!112.4!92.97
! LIVER A-ESTERASE VMAX (MG/H)
KM4=66.38!75.51 ! LIVER A-ESTERASE MICHAELIS-MENTON KM
PHH=1.07
PDD=1.08
PLL=1.09
PBRR=1.27
PFF=1.18
PRR=1.09

!
!
!
!
!
!

HEART/BLOOD PART. COEF.
DIAPHRAGM/BLOOD PART. COEF.
LIVER/BLOOD PART. COEF.
BRAIN/BLOOD PART. COEF.
FAT/BLOOD PART. COEF.
RICHLY PERFUSED TISSUE/BLOOD PART.

PSS=1.07

! SLOWLY PERFUSED TISSUE/BLOOD PART.

!-----PARATHION-SPECIFIC PARAMETERS-----!
CONSTANT
CONSTANT
CONSTANT
CONSTANT
(MG/H/KG
CONSTANT
(MG/L)
CONSTANT
(MG/H/KG
CONSTANT
(MG/H/KG
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
COEF.
CONSTANT
COEF.

MW=291.27
! MOLECULAR WEIGHT (G/MOL)
VMAX1=13.596!15.9!14.19 ! LIVER CP450 VMAX1 (MG/H/KG BW)
VMAX2=24.54!28.72!16.39 ! LIVER CP450 VMAX2 (MG/H)
VMAX2= 1.8085*vmax1!13.596!15.9!14.19 ! LIVER CP450 VMAX1
BW)
KM1=10.508!math7.573 ! LIVER CP450 MICHAELIS-MENTON KM1
KM2=24.699!15.437 ! LIVER CP450 MICHAELIS-MENTON KM2
BW)
KM2=2.0384*km1!15.437 ! LIVER CP450 MICHAELIS-MENTON KM2
BW)
PH=3.8
! HEART AND LUNGS/BLOOD PART. COEF.
PD=8
! DIAPHRAGM/BLOOD PART. COEF.
PL=3.8
! LIVER/BLOOD PART. COEF.
PBR=2.78
! BRAIN/BLOOD PART. COEF.
PF=96.7
! FAT/BLOOD PART. COEF.
PSK=8.7
! SKIN/BLOOD PART. COEF.
PR=3.8
! RICHLY PERFUSED TISSUE/BLOOD PART.
PS=2

! SLOWLY PERFUSED TISSUE/BLOOD PART.

!-----PARAOXON-SPECIFIC PARAMETERS-----!
CONSTANT MWW=275.21
! MOLECULAR WEIGHT (G/MOL)
CONSTANT VMAX3=48.72!57!93.6!39.21 ! PLASMA A-ESTERASE VMAX (MG/H)
CONSTANT KM3=61.92
! PLASMA A-ESTERASE MICHAELIS-MENTON KM
(MG/L)
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CONSTANT
CONSTANT
(MG/L)
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
CONSTANT
COEF.
CONSTANT
COEF.

VMAX4=80!93.6!76.51
KM4=50.08!55.04

! LIVER A-ESTERASE VMAX (MG/H)
! LIVER A-ESTERASE MICHAELIS-MENTON KM

PHH=1.07
PDD=1.08
PLL=1.09
PBRR=1.27
PFF=1.18
PSKK=.95
PRR=1.09

!
!
!
!
!
!
!

HEART/BLOOD PART. COEF.
DIAPHRAGM/BLOOD PART. COEF.
LIVER/BLOOD PART. COEF.
BRAIN/BLOOD PART. COEF.
FAT/BLOOD PART. COEF.
SKIN/BLOOD PART. COEF.
RICHLY PERFUSED TISSUE/BLOOD PART.

PSS=1.07

! SLOWLY PERFUSED TISSUE/BLOOD PART.

!-----DERIVED PARAMETERS-----!
QC=QCC*BW**0.74
QH=QHC*QC
QD=QDC*QC
QL=QLC*QC
QBR=QBRC*QC
QF=QFC*QC
QR=0.76*QC-QL-QBR
(L/H)
QS=.24*QC-QF-QSK-QD
(L/H)
VH=VHC*BW
VD=VDC*BW
VL=VLC*BW
VBR=VBRC*BW
VF=VFC*BW
VS=0.82*BW-VF-VSK-VD
VR=0.09*BW-VL-VBR-VH
VV=VVC*BW
VA=VAC*BW

! CARDIAC OUTPUT (L/H)
! BLOOD FLOW TO HEART AND LUNGS (L/H)
! BLOOD FLOW TO DIAPHRAGM (L/H)
! BLOOD FLOW TO LIVER (L/H)
! BLOOD FLOW TO BRAIN (L/H)
! BLOOD FLOW TO FAT (L/H)
! BLOOD FLOW TO RAPIDLY PERFUSED TISSUES
! BLOOD FLOW TO SLOWLY PERFUSED TISSUES
!
!
!
!
!
!
!
!
!

VOLUME
VOLUME
VOLUME
VOLUME
VOLUME
VOLUME
VOLUME
VOLUME
VOLUME

OF
OF
OF
OF
OF
OF
OF
OF
OF

HEART AND LUNGS (L)
DIAPHRAGM (L)
LIVER (L)
BRAIN (L)
FAT (L)
SLOWLY PERFUSED TISSUES (L)
RAPIDLY PERFUSED TISSUE (L)
POOLED VENOUS BLOOD (L)
ARTERIAL BLOOD (L)

!-----EXPOSURE DEFINITION-----!
DOSE=CDOSE*BW
DOS=CDOS*BW
DOSS=CDOSS*BW

! CHLORPYRIFOS ORAL DOSE

DOSEO=CDOSEO*BW
DOSO=CDOSO*BW
DOSSO=CDOSSO*BW

! CHLORPYRIFOS-OXON ORAL DOSE

DOSE=MPDOSE*BW
DOS=MPDOS*BW
DOSS=MPDOSS*BW

! METHYLPARATHION ORAL DOSE

DOSEO=MPDOSEO*BW
DOSO=MPDOSO*BW
DOSSO=MPDOSSO*BW

! METHYLPARAOXON ORAL DOSE
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DOSE=PDOSE*BW
DOS=PDOS*BW
DOSS=PDOSS*BW

! PARATHION ORAL DOSE

DOSEO=PDOSEO*BW
DOSO=PDOSO*BW
DOSSO=PDOSSO*BW

! PARAOXON ORAL DOSE

CONSTANT CDOSE=0
CONSTANT CDOS=0
CONSTANT CDOSS=0

! CHLORPYRIFOS ORAL DOSE (MG/KG)

CONSTANT MPDOSE=0
CONSTANT MPDOS=0
CONSTANT MPDOSS=0

! METHYLPARATHION ORAL DOSE (MG/KG)

CONSTANT PDOSE=0
CONSTANT PDOS=0
CONSTANT PDOSS=0

! PARATHION ORAL DOSE (MG/KG)

CONSTANT KA=1
CONSTANT KAA=1
CONSTANT KAAA=1

! FIRST ORDER ORAL UPTAKE RATE (1/HR)

IF
TO
IF
IF

! IF NO ORAL DOSE SET ABSORPTION RATE

(PDOSE.EQ.0.) KA=0.
0
(DOS.EQ.0) KAA=0.
(DOSS.EQ.0) KAAA=0.

CONSTANT CDOSEO=0
CONSTANT CDOSO=0
CONSTANT CDOSSO=0

! CHLORPYRIFOS-OXON ORAL DOSE (MG/KG)

CONSTANT MPDOSEO=0
CONSTANT MPDOSO=0
CONSTANT MPDOSSO=0

! METHYLPARAOXON ORAL DOSE (MG/KG)

CONSTANT PDOSEO=0
CONSTANT PDOSO=0
CONSTANT PDOSSO=0

! PARAOXON ORAL DOSE (MG/KG)

CONSTANT KAB=1
(1/HR)
CONSTANT KAAC=1
CONSTANT KAAAD=1

! OXON FIRST ORDER ORAL UPTAKE RATE

IF
TO
IF
IF

! IF NO ORAL DOSE SET ABSORPTION RATE

(PDOSEO.EQ.0.) KAB=0.
0
(DOSO.EQ.0) KAAC=0.
(DOSSO.EQ.0) KAAAD=0.

!-----SWEEP CONSTANTS-----!
CONSTANT CMN=.25

! SWEEP PARAMETER
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CONSTANT CMX=.25
CONSTANT CDL=.25

! SWEEP PARAMETER
! SWEEP PARAMETER

CONSTANT MPMN=.25
CONSTANT MPMX=.25
CONSTANT MPDL=.25

! SWEEP PARAMETER
! SWEEP PARAMETER
! SWEEP PARAMETER

CONSTANT PMN=.25
CONSTANT PMX=.25
CONSTANT PDL=.25

! SWEEP PARAMETER
! SWEEP PARAMETER
! SWEEP PARAMETER

!---------- PHARMACODYNAMIC MODEL PARAMETERS----------!
'** ACHE DYNAMIC PARAMETERS IN THE BRAIN TISSUE**'
CONSTANT ACTD=3255.6 ! TOTAL ENZYME CONC. (PM) IN DIAPHRAGM
(EBD)(BED)
CONSTANT ACTL=3466.7
! TOTAL ENZYME CONC. (PM) IN LIVER
CONSTANT ACTH=2604
! TOTAL ENZYME CONC. (PM) IN HEART
CONSTANT ACTM=2036!2790.9!500
! TOTAL ENZYME CONC. (PM) IN RBSC
BLOOD
CONSTANT ACTV=2790.9!498
! TOTAL ENZYME CONC. (PM) IN VENOUS
BLOOD
CONSTANT ACTMP=725.7!2036!2790.9!500
! TOTAL ENZYME CONC. (PM) IN
RBSC BLOOD
CONSTANT ACT=31227.3
! TOTAL ENZYME CONC. (PM) IN BR CON. add
pbs
CONSTANT Ki=1.45!.9
! INHIBITION ACHE (PM-1 H-1) add pbs
CONSTANT Ki2=.00000125
! INHIBITION ACHE (PM-1 H-1) add pbs
CONSTANT K2=50
! add pbs
CONSTANT zz=3
! add pbs
CONSTANT K5=.08!.114 !08
! REGENERATION OF ACHE (H-1)
CONSTANT K6=.01
! AGING OF ACHE (H-1)
CONSTANT K8=.0107
! DEGENERATION OF ACHE (H-1)
CONSTANT K7ab= 334.2
CONSTANT K7al=37.1
CONSTANT K7ah=27.9
CONSTANT K7abl=21.7!5.35!29.9
! RBSCS ACHE SYNTHSIS
CONSTANT K7ablP=7.7!21.7!5.35!29
! PLASMA ACHE SYNTHSIS
CONSTANT K7ad=34.8!25.2
'** BUTYRYLCHOLINESTERASE PHARMACODYNAMIC PARAMETERS**'
CONSTANT ACTBUb=14646
CONSTANT ACTBUL=2305
(BET)
CONSTANT ACTBUD=3422.2
(EBD)(BED)
CONSTANT ACTBUH=3425
CONSTANT ACTBUM=3761!2050
CONSTANT ACTBUM=2050
CONSTANT ACTBUV=2050
BLOOD

! TOTAL ENZYME CONC. (PM) IN BRAIN
! TOTAL ENZYME CONC. (PM) IN LIVER (EBT)
! TOTAL ENZYME CONC. (PM) IN DIAPHRAGM
!
!
!
!

TOTAL
TOTAL
TOTAL
TOTAL
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ENZYME
ENZYME
ENZYME
ENZYME

CONC.
CONC.
CONC.
CONC.

(PM)
(PM)
(PM)
(PM)

IN HEART
IN PLASMA
IN BLOOD
IN VENOUS

CONSTANT Ki2B=.00002044!.000005
! optIM INHIBITION
BUTERYLCHOLINESTERASE (PM-1 H-1)
CONSTANT K5B=.08
! REGENERATION OF (H-1)
CONSTANT K6B=.01
! AGING (H-1)
CONSTANT K7bb=156.7!34.13!43.17!34.1329994
! SYNTHESIS OF BRAIN
ACHE (H-1)
CONSTANT K7bl=24.7
! SYNTHESIS OF LIVER ACHE
CONSTANT K7db=36.62
! SYNTHESIS OF DIAPHRAGM ACHE
CONSTANT K7bbl=40.24!21.9
! SYNTHESIS OF PLASMA BUCHE ADJUSTED TO
PLASMA VOLUME
CONSTANT K7bh=36.6
! SYNTHESIS OF HEART ACHE
CONSTANT K7bblv=21.935
! SYNTHESIS OF VENOUS TOTAL ADJUSTED
TO VENOUS VOLUME
'** CARBOXYLESTERASE PHARMACODYNAMIC PARAMETERS**'
CONSTANT ACTCEb=163636.37
! TOTAL ENZYME CONC. (PM) IN BRAIN
CONSTANT ACTCEbf=426262.63
! TOTAL ENZYME CONC. (PM) IN BRAIN
II
CONSTANT ACTCEL=5310000
! TOTAL ENZYME CONC. (PM) IN LIVER
CONSTANT ACTCELf=13822500
! TOTAL ENZYME CONC. (PM) IN LIVER
caeII
CONSTANT ACTCEH=440986.667
! TOTAL ENZYME CONC. (PM) IN HEART
CONSTANT ACTCEHf=11480833.330
! TOTAL ENZYME CONC. (PM) IN HEART
II
CONSTANT ACTCEM=1244881.245
! TOTAL ENZYME CONC. (PM) IN
ARTERIAL BLOOD
CONSTANT ACTCEV=1244881.245
! TOTAL ENZYME CONC. (PM) IN
VENOUS BLOOD
CONSTANT ACTCEMf=3242424.242
! TOTAL ENZYME CONC. (PM) IN
ARTERIAL BLOOD II
CONSTANT ACTCEVf=3242424.242
! TOTAL ENZYME CONC. (PM) IN
VENOUS BLOOD II
CONSTANT ACTCED=866666.6667
! TOTAL ENZYME CONC. (PM) IN
DIAPHRAGM
CONSTANT ACTCEDf=311666.6667
! TOTAL ENZYME CONC. (PM) IN
DIAPHRAGM II
CONSTANT Ki2C=0.0000312!0.00000625 ! INHIBITION CARBOXYL ESTERASE
(PM-1 H-1)
CONSTANT K5C=.08
! REGENERATION OF (H-1)
CONSTANT K6C=.01
! AGING OF (H-1)
CONSTANT K7C=1751
! SYNTHESIS OF CAE I
CONSTANT K7CF=4561
! SYNTHESIS OF CAE II
(K8*ACTCEBF,10107)
CONSTANT K7bc=1751
! SYNTHESIS OF CAE I BRAIN (H-1)
CONSTANT K7lc=56817
! SYNTHESIS OF LIVER CAE I
CONSTANT K7dc=9273.3
! SYNTHESIS OF DIAPHRAGM CAE I
CONSTANT K7blc=13320.2
! SYNTHESIS OF BLOOD CAE I
CONSTANT K7hc=4718.6
! SYNTHESIS OF HEART CAE I
CONSTANT K7bd=4561
! SYNTHESIS OF BRAIN CAE II(H-1)
CONSTANT K7ld=147900.8
! SYNTHESIS OF LIVER CAE II
CONSTANT K7dd=3334.8
! SYNTHESIS OF DIAPHRAGM CAE II
CONSTANT K7bld=34693.9
! SYNTHESIS OF BLOOD CAE II
CONSTANT K7hd=122844.9

105

CONSTANT K8C=.0107

! DEGENERATION OF (H-1)

END

! END OF INITIAL

!-------------------------------------------------------------!
DYNAMIC
WRITE(99,10)T,PCHE
10..FORMAT(F12.5,F12.5,F12.5)
DISCRETE CAT1
CIZONE=48!24
!w=t-24
schedule cat2 .at. t+48!24
END
DISCRETE cat2
CIZONEe=96!48
!w=t-48
schedule cat3 .at. t+48
END
DISCRETE cat3
scdosop=.75
!w=t-72
CIZONE=144!72!0
schedule cat4 .at. t+48
END
DISCRETE cat4
!w=t-96
CIZONE=192!96
schedule cat5 .at. t+48!
END
DISCRETE cat5
!w=t-120
CIZONE=240!120!0
schedule cat6 .at. t+48!
END
DISCRETE cat6
CIZONE=288!144!1
schedule cat7 .at. t+48!
END
DISCRETE cat7
scdosop=1.35
CIZONE=336!168!0
schedule cat8 .at. t+48
END
DISCRETE cat8
CIZONE=384!192!1
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schedule cat9 .at. t+48!.0083
END
DISCRETE cat9
CIZONE=432!0
schedule cat10 .AT. T+48
END
DISCRETE cat10
CIZONE=480!1
schedule cat11 .at. t+48!.0083
END
DISCRETE cat11
CIZONE=264!0
schedule cat12 .at. t+48
END
DISCRETE cat12
CIZONE=288!1
schedule cat13 .at. t+48!
END
DISCRETE cat13
CIZONE=312!0
schedule cat14 .at. t+48
END
DISCRETE cat14
CIZONE=336!!1
schedule cat15 .at. t+48!.0083
END
DISCRETE cat15
CIZONE=360!0
schedule cat16 .AT. T+48
END
DISCRETE cat16
CIZONE=384!1
schedule cat17 .at. t+48!.0083
END
DISCRETE CAT17
CIZONE=408
!w=t-24
schedule cat18 .at. t+48
END
DISCRETE cat18
CIZONE=432
!w=t-48
schedule cat19 .at. t+48
END
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DISCRETE cat19
!w=t-72
CIZONE=456!0
schedule cat20 .at. t+48
END
DISCRETE cat20
!w=t-96
CIZONE=480
schedule cat2 .at. t+48!
END
DISCRETE cat21
CIZONE=504
schedule cat2 .at. t+48
END
END
!-------------------------------------------------------------!
DERIVATIVE
!K1=K2*ZZ
!KM2=2.0384*KM1
!KM3=1.3264*KM4
!VMAX2=1.8085*VMAX1
!VMAX4=1.642*VMAX3
!-----CONDITION FOR TERMINATION OF THE RUN-----!
TERMT (T.GE.TSTOP)
!-----OP EXPOSURE-----!
!-----ORAL DOSE MIXTURE-----!
RMR=-KA*MR
MR=DOSE*EXP(-KA*T)
RAO=KA*MR
AO=INTEG(RAO,0.)

!
!
!
!

RATE OF CHANGE IN THE STOMACH
AMOUNT REMAINING IN THE STOMACH
RATE OF AMOUNT ABSORBED
AMOUNT ABSORBED

RMRR=-KAA*MRR
MRR=DOS*EXP(-KAA*(T-8))
RAOO=KAA*MRR
AOO=INTEG(RAOO,0.)
RMRS=-KAAA*MRS
MRS=DOSS*EXP(-KAAA*(T-16))
RAOP=KAAA*MRS
AOP=INTEG(RAOP,0.)
!-----OXON EXPOSURE-----!
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!-----ORAL DOSE OF MIXTURE-----!
RMRB=-KAB*MRB
! RATE OF CHANGE IN THE STOMACH
MRB=DOSEO*EXP(-KAB*T)
! AMOUNT REMAINING IN THE STOMACH
RAOB=KAB*MRB
! RATE OF AMOUNT ABSORBED
AOB=INTEG(RAOB,0.)
! AMOUNT ABSORBED
!----- CHLORPYRIFOS IN VENOUS BLOOD-----!
RAV=(QF*CVF+QL*CVL+QS*CVS+QR*CVR+QBR*CVBR+QSK*CVSK+IV+QD*CVD)...
-QC*CV+rscap
! RATE OF CHLOPYRIFOS INPUT TO THE VENOUS
BLOOD(MG/H)
AV=INTEG(RAV,0.)
! AMOUNT IN THE VENOUS BLOOD (MG)
CV=AV/VV
! CONCENTRATION (MG/KG)
!-----CHLORPYRIFOS-OXON IN VENOUS BLOOD-----!
RAVO=(QF*CVFF+QL*CVLL+QS*CVSS+QR*CVRR+QBR*CVBRR+QSK*CVSKK+ivo+QD*CVD
D)...
-QC*CVO-RAM3+rsca-RINHCEVM-RINHCEVFM-RINHBUVM-RINHvM!RAG!+scA
! RATE OF CHLORPYRIFOS-OXON INPUT TO THE VENOUS BLOOD (MG/H)
AVO=INTEG(RAVO,0.)
! AMOUNT IN THE VENOUS BLOOD (MG)
CVO=AVO/VV
! CONCENTRATION (MG/KG)
ABV=CVO*1000000000/MWW
!-----A-ESTERASE ENZYME HYDROLYSIS OF CHLORPYRIFOS-OXON IN THE
VENOUS BLOOD -----!
RAM3=(VMAX3*CVO)/(KM3+CVO)
HYDROLYSIS(MG/H)
AM3=INTEG(RAM3,0.)
OXON(MG)

! RATE OF CHLORPYRIFOS-OXON
! AMOUNT OF HYDROLYSED CHLORPYRIFOS-

!----- CHLORPYRIFOS-OXON IN ARTERIAL BLOOD-----!
RAT=(QC*(CHHH-CAT))-RAM4-RINHCEMM-RINHCEMFM-RINHBUMM-RINHMM!
! RATE OF CHANGE (MG/HR)
AAT=INTEG(RAT,0.)
! AMOUNT (MG)'
CAT=AAT/VA
! CONCENTRATION (MG/L)
ABM=CAT*1000000000/MWW
! CONCENTRATION PM
RAM4=(VMAX3*CAT)/(KM3+CAT)
AM4=INTEG(RAM4,0.)
!-----CHLORPYRIFOS IN HEART+LUNGS-----!
RAH=QC*(CV-CA)
AH=INTEG(RAH,0.)
CH=AH/VH
CA=CH/PH

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)'
CONCENTRATION HEART/LUNGS (MG/L)
CONCENTRATION ARTERIAL HEART (MG/L)

!-----CHLORPYRIFOS-OXON IN HEART+LUNGS-----!
RAAH=(QC*(CVO-CHHH))-RINHCEHM-RINHCEHFM-RINHBUHM-RINHHM
! RATE OF CHANGE (MG/HR)
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AHH=INTEG(RAAH,0.)
CHH=AHH/VH
ABH=CHH*1000000000/MWW
CHHH=CHH/PHH

! AMOUNT (MG)'
! CONCENTRATION (MG/L)

!-----CHLORPYRIFOS IN DIAPHRAGM-----!
RAD=QD*(CA-CVD)
AD=INTEG(RAD,0.)
CD=AD/VD
!ABH=CDD*1000000000/MWW
CVD=CD/PD

! RATE OF CHANGE (MG/HR)
! AMOUNT (MG)'
! CONCENTRATION (MG/L)
! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS-OXON IN DIAPHRAGM-----!
RADD=(QD*(CAT-CVDD))-RINHCEDFM-RINHCEDM-RINHBUDM-RINHDM
! RATE OF CHANGE (MG/HR)
ADD=INTEG(RADD,0.)
! AMOUNT (MG)
CDD=ADD/VD
! CONCENTRATION (MG/L)
ABD=CVDD*1000000000/MWW
!ABD=CVDD*1000000000/MWW
CVDD=CDD/PDD
! CONCENTRATION IN VENOUS OUTFLOW (MG/L)
!-----CHLORPYRIFOS IN LIVER-----!
RAL=(QL*(CA-CVL))-RAM1-RAM2+RAO+RAOO+RAOP ! RATE OF CHANGE (MG/HR)
AL=INTEG(RAL,0.)
! AMOUNT (MG)
CL=AL/VL
! CONCENTRATION (MG/L)
CVL=AL/(VL*PL)
! CONCENTRATION IN VENOUS OUTFLOW (MG/L)
!-----CHLORPYRIFOS METABOLISM IN LIVER-----!
RAM1=(VMAX1*CVL)/(KM1+CVL)
AM1=INTEG(RAM1,0.)
RAM2=(VMAX2*CVL)/(KM2+CVL)
AM2=INTEG(RAM2,0.)

! RATE OF CHANGE (MG/HR)
! AMOUNT (C-OXON) (MG)
! AMOUNT (TCP) (MG)

!-----CHLORPYRIFOS-OXON IN LIVER-----!
RALL=(QL*(CAT-CVLL))+RAM1-RAMM+raob-RINHCELM-RINHCELFM...
-RINHBULM-RINHLM
! RATE OF CHANGE (MG/HR)
ALL=INTEG(RALL,0.)
! AMOUNT (MG)
CLL=ALL/VL
! CONCENTRATION (MG/L)
ABL=CVLL*1000000000/MWW
!ABL=CLL*1000000000/MWW
CVLL=ALL/(VL*PLL)
! CONCENTRATION IN VENOUS OUTFLOW (MG/L)
!-----CHLORPYRIFOS-OXON METABOLISM IN LIVER-----!
RAMM=(VMAX4*CVLL)/(KM4+CVLL)
AMM=INTEG(RAMM,0.)
! AMOUNT (TCP) (MG)
!-----CHLORPYRIFOS IN BRAIN-----!
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RABR=QBR*(CA-CVBR)
ABR=INTEG(RABR,0.)
CBR=ABR/VBR
CVBR=ABR/(VBR*PBR)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS-OXON IN BRAIN-----!
RABRR=(QBR*(CAT-CVBRR))-RINHCEBM-RINHCEBFM-RINHBUBM-RINHMC
! RATE OF CHANGE (MG/HR)
ABRR=INTEG(RABRR,0.)
! AMOUNT (MG)
CBRR=ABRR/VBR
! CONCENTRATION (MG/L)
AB=CBRR*1000000000/MWW
CVBRR=ABRR/(VBR*PBRR)

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS IN FAT-----!
RAF=QF*(CA-CVF)
AF=INTEG(RAF,0.)
CF=AF/VF
CVF=AF/(VF*PF)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS-OXON IN FAT-----!
RAFF=QF*(CAT-CVFF)
AFF=INTEG(RAFF,0.)
CFF=AFF/VF
CVFF=AFF/(VF*PFF)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS IN SLOWLY PERFUSED TISSUES-----!
RAS=QS*(CA-CVS)
AS=INTEG(RAS,0.)
CS=AS/VS
CVS=CS/PS

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS-OXON IN SLOWLY PERFUSED TISSUES-----!
RASS=QS*(CAT-CVSS)
ASS=INTEG(RASS,0.)
CSS=ASS/VS
CVSS=CSS/PSS

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS IN RAPIDLY PERFUSED TISSUES-----!
RAR=QR*(CA-CVR)
AR=INTEG(RAR,0.)
CR=AR/VR
CVR=CR/PR

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS-OXON IN RAPIDLY PERFUSED TISSUES-----!
RARR=QR*(CAT-CVRR)

! RATE OF CHANGE (MG/HR)
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ARR=INTEG(RARR,0.)
CRR=ARR/VR
CVRR=CRR/PRR

! AMOUNT (MG)
! CONCENTRATION (MG/L)
! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----CHLORPYRIFOS -> TCP) Model 1-----!
CONSTANT KmHcp= 24.0
CONSTANT VmHcp= 273.0

! CONCENTRATION (µM/L)
! RATE OF CHANGE (µM /HR)

!-----LIVER(OXON ->TCP) AEST Model 2-----!
CONSTANT KMlst= 240.0
CONSTANT VMl= 74421.0

! CONCENTRATION (µM/L)
! RATE OF CHANGE (µM /HR)

!-----BLOOD(OXON -> TCP) AEST Model 2-----!
CONSTANT KMblst= 250.0
CONSTANT VMbl= 57003.0

! CONCENTRATION (µM/L)
! RATE OF CHANGE (µM /HR)

!----- METHYLPARATHION IN VENOUS BLOOD-----!
RAV=(QF*CVF+QL*CVL+QS*CVS+QR*CVR+QBR*CVBR+QSK*CVSK+IV+QD*CVD)...
-QC*CV+rscap
! RATE OF METHYLPARATHION INPUT TO THE
VENOUS BLOOD(MG/H)
AV=INTEG(RAV,0.)
! AMOUNT IN THE VENOUS BLOOD (MG)
CV=AV/VV
! CONCENTRATION (MG/KG)
!-----METHYLPARAOXON IN VENOUS BLOOD-----!
RAVO=(QF*CVFF+QL*CVLL+QS*CVSS+QR*CVRR+QBR*CVBRR+QSK*CVSKK+ivo+QD*CVD
D)...
-QC*CVO-RAM3+rsca-RINHCEVM-RINHCEVFM-RINHBUVM-RINHvM!RAG!+scA
!RATE OF METHYLPARAOXON INPUT TO THE VENOUS BLOOD(MG/H)
AVO=INTEG(RAVO,0.)
! AMOUNT IN THE VENOUS BLOOD (MG)
CVO=AVO/VV
! CONCENTRATION (MG/KG)
ABV=CVO*1000000000/MWW
!-----A-ESTERASE ENZYME HYDROLYSIS OF METHYLPARAOXON IN VENOUS
BLOOD-----!
RAM3=(VMAX3*CVO)/(KM3+CVO)
(MG/H)
AM3=INTEG(RAM3,0.)
(MG)

! RATE OF METHYLPARAOXON HYDROLYSIS
! AMOUNT OF HYDROLYSED METHYLPARAOXON

!-----METHYLPARAOXON IN ARTERIAL BLOOD-----!
RAT=(QC*(CHHH-CAT))-RAM4-RINHCEMM-RINHCEMFM-RINHBUMM-RINHMM!
! RATE OF CHANGE (MG/HR)
AAT=INTEG(RAT,0.)
! AMOUNT (MG)'
CAT=AAT/VA
! CONCENTRATION (MG/L)
ABM=CAT*1000000000/MWW
! CONCENTRATION PM
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RAM4=(VMAX3*CAT)/(KM3+CAT)
AM4=INTEG(RAM4,0.)
!-----METHYLPARATHION IN HEART+LUNGS-----!
RAH=QC*(CV-CA)
AH=INTEG(RAH,0.)
CH=AH/VH
CA=CH/PH

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)'
CONCENTRATION HEART/LUNGS (MG/L)
CONCENTRATION ARTERIAL (MG/L)

!-----METHYLPARAOXON IN HEART+LUNGS-----!
RAAH=(QC*(CVO-CHHH))-RINHCEHM-RINHCEHFM-RINHBUHM-RINHHM
! RATE OF CHANGE (MG/HR)
AHH=INTEG(RAAH,0.)
! AMOUNT (MG)'
CHH=AHH/VH
! CONCENTRATION (MG/L)
ABH=CHH*1000000000/MWW
CHHH=CHH/PHH
!-----METHYLPARATHION IN DIAPHRAGM-----!
RAD=QD*(CA-CVD)
AD=INTEG(RAD,0.)
CD=AD/VD
!ABH=CDD*1000000000/MWW

! RATE OF CHANGE (MG/HR)
! AMOUNT (MG)'
! CONCENTRATION (MG/L)

CVD=CD/PD

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARAOXON IN DIAPHRAGM-----!
RADD=(QD*(CAT-CVDD))-RINHCEDFM-RINHCEDM-RINHBUDM-RINHDM
! RATE OF CHANGE (MG/HR)
ADD=INTEG(RADD,0.)
! AMOUNT (MG)
CDD=ADD/VD
! CONCENTRATION (MG/L)
ABD=CVDD*1000000000/MWW
!ABD=CVDD*1000000000/MWW
CVDD=CDD/PDD

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARATHION IN LIVER-----!
RAL=(QL*(CA-CVL))-RAM1-RAM2+RAO+RAOO+RAOP
! RATE OF CHANGE (MG/HR)
AL=INTEG(RAL,0.)
! AMOUNT (MG)
CL=AL/VL
! CONCENTRATION (MG/L)
CVL=AL/(VL*PL)

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARATHION METABOLISM IN LIVER-----!
RAM1=(VMAX1*CVL)/(KM1+CVL)
AM1=INTEG(RAM1,0.)
RAM2=(VMAX2*CVL)/(KM2+CVL)

! RATE OF CHANGE (MG/HR)
! AMOUNT (METHYLPARAOXON) (MG)
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AM2=INTEG(RAM2,0.)

! AMOUNT (PNP) (MG)

!-----METHYLPARAOXON IN LIVER-----!
RALL=(QL*(CAT-CVLL))+RAM1-RAMM+raob-RINHCELM-RINHCELFM...
-RINHBULM-RINHLM
! RATE OF CHANGE (MG/HR)
ALL=INTEG(RALL,0.)
! AMOUNT (MG)
CLL=ALL/VL
! CONCENTRATION (MG/L)
ABL=CVLL*1000000000/MWW
!ABL=CLL*1000000000/MWW
CVLL=ALL/(VL*PLL)

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARAOXON METABOLISM IN LIVER-----!
RAMM=(VMAX4*CVLL)/(KM4+CVLL)
AMM=INTEG(RAMM,0.)
! AMOUNT (PNP) (MG)
!-----METHYLPARATHION IN BRAIN-----!
RABR=QBR*(CA-CVBR)
ABR=INTEG(RABR,0.)
CBR=ABR/VBR
CVBR=ABR/(VBR*PBR)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARAOXON IN BRAIN-----!
RABRR=(QBR*(CAT-CVBRR))-RINHCEBM-RINHCEBFM-RINHBUBM-RINHMc
! RATE OF CHANGE (MG/HR)
ABRR=INTEG(RABRR,0.)
! AMOUNT (MG)
CBRR=ABRR/VBR
! CONCENTRATION (MG/L)
AB=CBRR*1000000000/MWW
CVBRR=ABRR/(VBR*PBRR)

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARATHION IN FAT-----!
RAF=QF*(CA-CVF)
AF=INTEG(RAF,0.)
CF=AF/VF
CVF=AF/(VF*PF)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION VENOUS OUTFLOW (MG/L)

!-----METHYLPARAOXON IN FAT-----!
RAFF=QF*(CAT-CVFF)
AFF=INTEG(RAFF,0.)
CFF=AFF/VF
CVFF=AFF/(VF*PFF)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARATHION IN SLOWLY PERFUSED TISSUES-----!
RAS=QS*(CA-CVS)
AS=INTEG(RAS,0.)

! RATE OF CHANGE (MG/HR)
! AMOUNT (MG)
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CS=AS/VS
CVS=CS/PS

! CONCENTRATION (MG/L)
! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARAOXON IN SLOWLY PERFUSED TISSUES-----!
RASS=QS*(CAT-CVSS)
ASS=INTEG(RASS,0.)
CSS=ASS/VS
CVSS=CSS/PSS

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARATHION IN RAPIDLY PERFUSED TISSUES-----!
RAR=QR*(CA-CVR)
AR=INTEG(RAR,0.)
CR=AR/VR
CVR=CR/PR

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----METHYLPARAOXON IN RAPIDLY PERFUSED TISSUES-----!
RARR=QR*(CAT-CVRR)
ARR=INTEG(RARR,0.)
CRR=ARR/VR
CVRR=CRR/PRR

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!----- PARATHION IN VENOUS BLOOD-----!
RAV=(QF*CVF+QL*CVL+QS*CVS+QR*CVR+QBR*CVBR+QSK*CVSK+IV+QD*CVD)...
-QC*CV+rscap
! RATE OF PARATHION INPUT TO THE VENOUS
BLOOD(MG/H)
AV=INTEG(RAV,0.)
! AMOUNT IN THE VENOUS BLOOD (MG)
CV=AV/VV
! CONCENTRATION (MG/KG)
!-----PARAOXON IN VENOUS BLOOD-----!
RAVO=(QF*CVFF+QL*CVLL+QS*CVSS+QR*CVRR+QBR*CVBRR+QSK*CVSKK+ivo+QD*CVD
D)...
-QC*CVO-RAM3+rsca-RINHCEVM-RINHCEVFM-RINHBUVM-RINHvM!RAG!+scA
! RATE OF PARAOXONN INPUT TO THE VENOUS BLOOD(MG/H)
AVO=INTEG(RAVO,0.)
! AMOUNT IN THE VENOUS BLOOD (MG)
CVO=AVO/VV
! CONCENTRATION (MG/KG)
ABV=CVO*1000000000/MWW
!-----A-ESTERASE ENZYME HYDROLYSIS OF PARAOXON IN THE VENOUS BLOOD----!
RAM3=(VMAX3*CVO)/(KM3+CVO)
AM3=INTEG(RAM3,0.)

! RATE OF PARAOXON HYDROLYSIS (MG/H)
! AMOUNT OF HYDROLYSED PARAOXON (MG)

!----- PARAOXON IN ARTERIAL BLOOD-----!
RAT=(QC*(CHHH-CAT))-RAM4-RINHCEMM-RINHCEMFM-RINHBUMM-RINHMM!
! RATE OF CHANGE (MG/HR)
AAT=INTEG(RAT,0.)
! AMOUNT (MG)'
CAT=AAT/VA
! CONCENTRATION (MG/L)
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ABM=CAT*1000000000/MWW

! CONCENTRATION PM

RAM4=(VMAX3*CAT)/(KM3+CAT)
AM4=INTEG(RAM4,0.)
!-----PARATHION IN HEART+LUNGS-----!
RAH=QC*(CV-CA)
AH=INTEG(RAH,0.)
CH=AH/VH
CA=CH/PH

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)'
CONCENTRATION HEART/LUNGS (MG/L)
CONCENTRATION ARTERIAL (MG/L)

!-----PARAOXON IN HEART+LUNGS-----!
RAAH=(QC*(CVO-CHHH))-RINHCEHM-RINHCEHFM-RINHBUHM-RINHHM
! RATE OF CHANGE (MG/HR)
AHH=INTEG(RAAH,0.)
! AMOUNT (MG)'
CHH=AHH/VH
! CONCENTRATION (MG/L)
ABH=CHH*1000000000/MWW
CHHH=CHH/PHH
!-----PARATHION IN DIAPHRAGM-----!
RAD=QD*(CA-CVD)
AD=INTEG(RAD,0.)
CD=AD/VD
!ABH=CDD*1000000000/MWW

! RATE OF CHANGE (MG/HR)
! AMOUNT (MG)'
! CONCENTRATION (MG/L)

CVD=CD/PD

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARAOXON IN DIAPHRAGM-----!
RADD=(QD*(CAT-CVDD))-RINHCEDFM-RINHCEDM-RINHBUDM-RINHDM
! RATE OF CHANGE (MG/HR)
ADD=INTEG(RADD,0.)
! AMOUNT (MG)
CDD=ADD/VD
! CONCENTRATION (MG/L)
ABD=CVDD*1000000000/MWW
!ABD=CVDD*1000000000/MWW
CVDD=CDD/PDD

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARATHION IN LIVER-----!
RAL=(QL*(CA-CVL))-RAM1-RAM2+RAO+RAOO+RAOP
! RATE OF CHANGE (MG/HR)
AL=INTEG(RAL,0.)
! AMOUNT (MG)
CL=AL/VL
! CONCENTRATION (MG/L)
CVL=AL/(VL*PL)

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARATHION METABOLISM IN LIVER-----!
RAM1=(VMAX1*CVL)/(KM1+CVL)

! RATE OF CHANGE (MG/HR)
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AM1=INTEG(RAM1,0.)
RAM2=(VMAX2*CVL)/(KM2+CVL)
AM2=INTEG(RAM2,0.)

! AMOUNT (PARAOXON) (MG)
! AMOUNT (PNP) (MG)

!-----PARAOXON IN LIVER-----!
RALL=(QL*(CAT-CVLL))+RAM1-RAMM+raob-RINHCELM-RINHCELFM...
-RINHBULM-RINHLM! RATE OF CHANGE (MG/HR)
ALL=INTEG(RALL,0.)
! AMOUNT (MG)
CLL=ALL/VL
! CONCENTRATION (MG/L)
ABL=CVLL*1000000000/MWW
!ABL=CLL*1000000000/MWW
CVLL=ALL/(VL*PLL)

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARAOXON METABOLISM IN LIVER-----!
RAMM=(VMAX4*CVLL)/(KM4+CVLL)
AMM=INTEG(RAMM,0.)
! AMOUNT (PNP) (MG)
!-----PARATHION IN BRAIN-----!
RABR=QBR*(CA-CVBR)
ABR=INTEG(RABR,0.)
CBR=ABR/VBR
CVBR=ABR/(VBR*PBR)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARAOXON IN BRAIN-----!
RABRR=(QBR*(CAT-CVBRR))-RINHCEBM-RINHCEBFM-RINHBUBM-RINHMc
! RATE OF CHANGE (MG/HR)
ABRR=INTEG(RABRR,0.)
! AMOUNT (MG)
CBRR=ABRR/VBR
! CONCENTRATION (MG/L)
AB=CBRR*1000000000/MWW
CVBRR=ABRR/(VBR*PBRR)

! CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARATHION IN FAT-----!
RAF=QF*(CA-CVF)
AF=INTEG(RAF,0.)
CF=AF/VF
CVF=AF/(VF*PF)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION VENOUS OUTFLOW (MG/L)

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARAOXON IN FAT-----!
RAFF=QF*(CAT-CVFF)
AFF=INTEG(RAFF,0.)
CFF=AFF/VF
CVFF=AFF/(VF*PFF)

!-----PARATHION IN SLOWLY PERFUSED TISSUES-----!
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RAS=QS*(CA-CVS)
AS=INTEG(RAS,0.)
CS=AS/VS
CVS=CS/PS

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARAOXON IN SLOWLY PERFUSED TISSUES-----!
RASS=QS*(CAT-CVSS)
ASS=INTEG(RASS,0.)
CSS=ASS/VS
CVSS=CSS/PSS

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARATHION IN RAPIDLY PERFUSED TISSUES-----!
RAR=QR*(CA-CVR)
AR=INTEG(RAR,0.)
CR=AR/VR
CVR=CR/PR

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PARAOXON IN RAPIDLY PERFUSED TISSUES-----!
RARR=QR*(CAT-CVRR)
ARR=INTEG(RARR,0.)
CRR=ARR/VR
CVRR=CRR/PRR

!
!
!
!

RATE OF CHANGE (MG/HR)
AMOUNT (MG)
CONCENTRATION (MG/L)
CONCENTRATION IN VENOUS OUTFLOW (MG/L)

!-----PHARMACODYNAMICS OF ACETYLCHOLINESTERSE-----!
RAC=K7ab-K8*AC+K5*ACA+K5*ABACa-KI*AB*AC-k1*ab*ac+k2*abac-KI2*ABAC*AB
AC=INTEG(RAC,act)
ACTIVITY=((AC+abac)/act)*100
ACTIVITYHI=ACTIVITY*1
RACA=Ki*AB*AC-K5*ACA-k6*aca
ACA=INTEG(RACA,0.)

! EQ 1

RABAC=K1*AB*AC-k2*ABAC-Ki2*ABAC*ab+k5*abaca!-k6*abaca
ABAC=INTEG(RABAC,0.)
RABACA=ki2*ABAC*ab-K5*ABACA-K6*ABACA
! EQ 3
ABACA=INTEG(RABACA,0.)
RABACAM=(RABACA*VBR*.0000000001)*MWW
rage=k6*aca+K5*ABACA
age=integ(rage,0.)
rreg=k5*aca+k5*abaca
reg=integ(rreg,0.)
RDEG=K8*AC
DEG=INTEG(RDEG,0.)
RINH=KI*AB*AC+KI2*AB*ABAC
! ACHE BINDING RATE
INH=INTEG(RINH,0.)
RINHMc=(RINH*VBR*.0000000001)*MWW
!-----BRAIN-BUCHE-----!
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! EQ 2

RACABUb=Ki2b*AB*ACBUb-K5*ACABUb-K6*ACABUb ! RATE OF CHANGE CHEMICAL
BOUND TO ACHE
ACABUb=INTEG(RACABUb,0.)
RACBUb=+K7bb-K8*ACBUb+K5*ACABUb-Ki2b*AB*ACBUb !RATE OF CHANGE CONC.
OF ACHE
ACBUb=INTEG(RACBUb,ACTBUb)
ACTIVITYBUb=(ACBUb/ACTBUb)*100
! ACHE ACTIVITY
RDEGBUb=K8*ACBUb
DEGBUb=INTEG(RDEGBUb,0.)
RAGEBUb=K6*ACABUb
! ACHE AGING RATE
AGEBUb=INTEG(RAGEBUb,0.)
RINHBUb=Ki2b*AB*ACBUb
! ACHE BINDING RATE
INHBUb=INTEG(RINHBUb,0.)
RINHBUBM=(RINHBUB*VBR*.0000000001)*MWW
!-----BRAIN CARBOXYL ESTERASE-----!
RACACEB=Ki2c*AB*ACCEB-K5*ACACEB-K6*ACACEB ! RATE OF CHANGE CHEMICAL
BOUND TO ACHE
ACACEB=INTEG(RACACEB,0.)
RACCEB=+K7bC-K8*ACCEB+K5*ACACEB-Ki2c*AB*ACCEB ! RATE OF CHANGE
CONC. OF ACHE
ACCEB=INTEG(RACCEB,ACTCEB)
ACTIVITYCEB=(ACCEB/ACTCEB)*100
! ACHE ACTIVITY
RDEGCEB=K8*ACCEB
DEGCEB=INTEG(RDEGCEB,0.)
RAGECEB=K6*ACACEB
! ACHE AGING RATE
AGECEB=INTEG(RAGECEB,0.)
RINHCEB=Ki2c*AB*ACCEB
! ACHE BINDING RATE
INHCEB=INTEG(RINHCEB,0.)
RINHCEBM=(RINHCEB*VBR*.0000000001)*MWW
!-----BRAIN CARBOXYL ESTERASE II-----!
RACACEBF=Ki2c*AB*ACCEBF-K5*ACACEBF-K6*ACACEBF ! RATE OF CHANGE
CHEMICAL BOUND TO ACHE
ACACEBF=INTEG(RACACEBF,0.)
RACCEBF=+K7bd-K8*ACCEBF+K5*ACACEBF-Ki2c*AB*ACCEBF ! RATE OF CHANGE
CONC. OF ACHE
ACCEBF=INTEG(RACCEBF,ACTCEBF)
ACTIVITYCEBF=(ACCEBF/ACTCEBF)*100
! ACHE ACTIVITY
RDEGCEBF=K8*ACCEBF
DEGCEBF=INTEG(RDEGCEBF,0.)
RAGECEBF=K6*ACACEBF
! ACHE AGING RATE
AGECEBF=INTEG(RAGECEBF,0.)
RINHCEBF=Ki2c*AB*ACCEBF
! ACHE BINDING RATE
INHCEBF=INTEG(RINHCEBF,0.)
RINHCEBFM=(RINHCEBF*VBR*.0000000001)*MWW
ACTIVITYCAB=0.5*(ACTIVITYCEB+ACTIVITYCEBF)
!-----LIVER ACHE-----!
RACl=K7al-K8*ACl+K5*ACAl+K5*ABACal-KI*ABl*ACl-k1*abl*acl+k2*abaclKI2*ABACl*ABl
ACl=INTEG(RACl,actl)
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ACTIVITYl=((ACl+ABACl)/actl)*100
RACAl=Ki*ABl*ACl-K5*ACAl-K6*ACAL
! EQ 1
ACAl=INTEG(RACAl,0.)
RBl=Ki*ABl*ACl+ki2*ABACl*ABl
! EQ 1
Bl=INTEG(RBl,0.)
RABACl=K1*ABl*ACl-k2*ABACl-Ki2*ABACl*abl!+k5*abacal!-K6*ABACL ! EQ 2
ABACl=INTEG(RABACl,0.)
RABACAl=ki2*ABACl*abl-K5*ABACAl-K6*ABACAL
! EQ 2
ABACAl=INTEG(RABACAl,0.)
RDEGl=K8*ACl
DEGl=INTEG(RDEGl,0.)
RAGEl=K6*ACAl
! ACHE AGING RATE
AGEl=INTEG(RAGEl,0.)
RINHl=KI*ABl*ACl+KI2*ABl*ABACl
! ACHE BINDING RATE
INHl=INTEG(RINHl,0.)
RINHLM=(RINHL*VL*.0000000001)*MWW
!-----LIVER-BUCHE-----!
RACABUL=Ki2b*ABL*ACBUL-K5*ACABUL-K6*ACABUL
! RATE OF CHANGE
CHEMICAL BOUND TO ACHE
ACABUL=INTEG(RACABUL,0.)
RACBUL=+K7bl-K8*ACBUL+K5*ACABUL-Ki2b*ABL*ACBUL ! RATE OF CHANGE
CONC. OF ACHE
ACBUL=INTEG(RACBUL,ACTBUL)
ACTIVITYBUL=(ACBUL/ACTBUL)*100
! ACHE ACTIVITY
RDEGBUL=K8*ACBUL
DEGBUL=INTEG(RDEGBUL,0.)
RAGEBUL=K6*ACABUL
! ACHE AGING RATE
AGEBUL=INTEG(RAGEBUL,0.)
RINHBUL=Ki2b*ABL*ACBUL
! ACHE BINDING RATE
INHBUL=INTEG(RINHBUL,0.)
RINHBULM=(RINHBUL*VL*.0000000001)*MWW
!-----LIVER CARBOXYL ESTERASE-----!
RACACEL=Ki2c*ABL*ACCEL-K5*ACACEL-K6*ACACEL
! RATE OF CHANGE
CHEMICAL BOUND TO ACHE
ACACEL=INTEG(RACACEL,0.)
RACCEL=+K7lc-K8*ACCEL+K5*ACACEL-Ki2c*ABL*ACCEL
! RATE OF CHANGE
CONC. OF ACHE
ACCEL=INTEG(RACCEL,ACTCEL)
ACTIVITYCEL=(ACCEL/ACTCEL)*100
! ACHE ACTIVITY
RDEGCEL=K8*ACCEL
DEGCEL=INTEG(RDEGCEL,0.)
RAGECEL=K6*ACACEL
AGECEL=INTEG(RAGECEL,0.)

! ACHE AGING RATE

RINHCEL=Ki2c*ABL*ACCEL
INHCEL=INTEG(RINHCEL,0.)

! ACHE BINDING RATE
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RINHCELM=(RINHCEL*VL*.0000000001)*MWW
!-----LIVER CARBOXYL ESTERASE II-----!
RACACELf=Ki2c*ABL*ACCELf-K5*ACACELf-K6*ACACELf
CHEMICAL BOUND TO ACHE
ACACELf=INTEG(RACACELf,0.)

! RATE OF CHANGE

RACCELf=+K7ld-K8*ACCELf+K5*ACACELf-Ki2c*ABL*ACCELf ! RATE OF CHANGE
CONCEN. OF ACHE
ACCELf=INTEG(RACCELf,ACTCELf)
ACTIVITYCELf=(ACCELf/ACTCELf)*100
! ACHE ACTIVITY
RDEGCELf=K8*ACCELf
DEGCELf=INTEG(RDEGCELf,0.)
RAGECELf=K6*ACACELf
AGECELf=INTEG(RAGECELf,0.)

! ACHE AGING RATE

RINHCELf=Ki2c*ABL*ACCELf
INHCELf=INTEG(RINHCELf,0.)

! ACHE BINDING RATE

RINHCELFM=(RINHCELF*VL*.0000000001)*MWW
activitycl=0.5*(activitycel+activitycelf)
!-----DIAPHRAGM ACHE-----!
RACd=K7ad-K8*ACd+K5*ACAd+K5*ABACad-KI*ABd*ACd-k1*abd*acd+k2*abacdKI2*ABACd*ABd
ACd=INTEG(RACd,actd)
!ACd=ACTd-ACAd-ABACd-ABACAd+K7ad-DEGd
ACTIVITYd=((ACd+ABACd)/actd)*100
RACAd=Ki*ABd*ACd-K5*ACAd-K6*ACAD
ACAd=INTEG(RACAd,0.)
RBd=Ki*ABd*ACd+ki*ABACd*ABd
Bd=INTEG(RBd,0.)

! EQ 1
! EQ 1

RABACd=K1*ABd*ACd-k2*ABACd-Ki2*ABACd*abd!+k5*abacad
ABACd=INTEG(RABACd,0.)

! EQ 2

RABACAd=ki2*ABACd*abd-K5*ABACAd-K6*ABACAD
ABACAd=INTEG(RABACAd,0.)

! EQ 2

RDEGd=K8*ACd
DEGd=INTEG(RDEGd,0.)
RAGEd=K6*ACAd
AGEd=INTEG(RAGEd,0.)

! ACHE AGING RATE

RINHd=KI*ABd*ACd+KI2*ABd*ABACd
INHd=INTEG(RINHd,0.)

! ACHE BINDING RATE
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RINHDM=(RINHD*VD*.0000000001)*MWW
!-----DIAPHRAGM BUCHE-----!
RACABUD=Ki2b*ABD*ACBUD-K5*ACABUD-K6*ACABUD
CHEMICAL BOUND TO ACHE
ACABUD=INTEG(RACABUD,0.)

! RATE OF CHANGE

RACBUD=+K7db-K8*ACBUD+K5*ACABUD-Ki2b*ABD*ACBUD
! RATE OF CHANGE
CONCEN. OF ACHE
ACBUD=INTEG(RACBUD,ACTBUD)
ACTIVITYBUD=(ACBUD/ACTBUD)*100
! ACHE ACTIVITY
RDEGBUD=K8*ACBUD
DEGBUD=INTEG(RDEGBUD,0.)
RAGEBUD=K6*ACABUD
AGEBUD=INTEG(RAGEBUD,0.)

! ACHE AGING RATE

RINHBUD=Ki2b*ABD*ACBUD
! ACHE BINDING RATE
INHBUD=INTEG(RINHBUD,0.)
RINHBUDM=(RINHBUD*VD*.0000000001)*MWW
RSYNBUD=K7*(1-ACBUD/ACTBUD)
! ACHE SYNTHESIS RATE
SYNBUD=INTEG(RSYNBUD,0.)
!-----DIAPHRAGM CARBOXYLESTERASE-----!
RACACED=Ki2c*ABD*ACCED-K5*ACACED-K6*ACACED
CHEMICAL BOUND TO ACHE
ACACED=INTEG(RACACED,0.)

! RATE OF CHANGE

RACCED=+K7dc-K8*ACCED+K5*ACACED-Ki2c*ABD*ACCED ! RATE OF CHANGE
CONCEN. OF ACHE
ACCED=INTEG(RACCED,ACTCED)
ACTIVITYCED=(ACCED/ACTCED)*100
! ACHE ACTIVITY
RDEGCED=K8*ACCED
DEGCED=INTEG(RDEGCED,0.)
RAGECED=K6*ACACED
AGECED=INTEG(RAGECED,0.)

! ACHE AGING RATE

RINHCED=Ki2c*ABD*ACCED
! ACHE BINDING RATE
INHCED=INTEG(RINHCED,0.)
RINHCEDM=(RINHCED*VD*.0000000001)*MWW
!-----DIAPHRAGM CARBOXYLESTERASE II-----!
RACACEDf=Ki2c*ABD*ACCEDf-K5*ACACEDf-K6*ACACEDf
CHEMICAL BOUND TO ACHE
ACACEDf=INTEG(RACACEDf,0.)

! RATE OF CHANGE

RACCEDf=+K7dd-K8*ACCEDf+K5*ACACEDf-Ki2c*ABD*ACCEDf
CONC. OF ACHE
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! RATE OF CHANGE

ACCEDf=INTEG(RACCEDf,ACTCEDf)
ACTIVITYCEDf=(ACCEDf/ACTCEDf)*100

! ACHE ACTIVITY

RDEGCEDf=K8*ACCEDf
DEGCEDf=INTEG(RDEGCEDf,0.)
RAGECEDf=K6*ACACEDf
AGECEDf=INTEG(RAGECEDf,0.)

! ACHE AGING RATE

RINHCEDf=Ki2c*ABD*ACCEDf
! ACHE BINDING RATE
INHCEDf=INTEG(RINHCEDf,0.)
RINHCEDFM=(RINHCEDF*VD*.0000000001)*MWW
RSYNCEDf=K7*(1-ACCEDf/ACTCEDf)
! ACHE SYNTHESIS RATE
SYNCEDf=INTEG(RSYNCEDf,0.)
activitycd=0.5*(activityced+activitycedf)
!-----HEART ACHE-----!
RACh=K7ah-K8*ACh+K5*ACAh+K5*ABACah-KI*ABh*ACh-k1*abh*ach+k2*abachKI2*ABACh*ABh
ACh=INTEG(RACh,acth)
ACTIVITYh=((ACh+ABACh)/acth)*100
RACAh=Ki*ABh*ACh-K5*ACAh-K6*ACAH
! EQ 1
ACAh=INTEG(RACAh,0.)
RBh=Ki*ABh*ACh+ki2*ABACh*ABh
Bh=INTEG(RBh,0.)

! EQ 1

RABACh=K1*ABh*ACh-k2*ABACh-Ki2*ABACh*abh!+k5*abacah
ABACh=INTEG(RABACh,0.)

! EQ 2

RABACAh=ki2*ABACh*abh-K5*ABACAh-K6*ABACAH
ABACAh=INTEG(RABACAh,0.)

! EQ 2

RDEGh=K8*ACh
DEGh=INTEG(RDEGh,0.)
RAGEh=K6*ACAh
AGEh=INTEG(RAGEh,0.)

! ACHE AGING RATE

RINHh=KI*ABh*ACh+KI2*ABh*ABACh
INHh=INTEG(RINHh,0.)
RINHHM=(RINHH*VH*.0000000001)*MWW

! ACHE BINDING RATE

!-----HEART BUCHE-----!
RACABUH=Ki2b*ABH*ACBUH-K5*ACABUH-K6*ACABUH ! RATE OF CHANGE CHEMICAL
BOUND TO ACHE
ACABUH=INTEG(RACABUH,0.)
RACBUH=+K7bh-K8*ACBUH+K5*ACABUH-Ki2b*ABH*ACBUH ! RATE OF CHANGE
CONC. OF ACHE
ACBUH=INTEG(RACBUH,ACTBUH)
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ACTIVITYBUH=(ACBUH/ACTBUH)*100

! ACHE ACTIVITY

RDEGBUH=K8*ACBUH
DEGBUH=INTEG(RDEGBUH,0.)
RAGEBUH=K6*ACABUH
AGEBUH=INTEG(RAGEBUH,0.)

! ACHE AGING RATE

RINHBUH=Ki2b*ABH*ACBUH
! ACHE BINDING RATE
INHBUH=INTEG(RINHBUH,0.)
RINHBUHM=(RINHBUH*VH*.0000000001)*MWW
!-----HEART CARBOXYL I-----!
RACACEH=Ki2c*ABH*ACCEH-K5*ACACEH-K6*ACACEH
CHEMICAL BOUND TO ACHE
ACACEH=INTEG(RACACEH,0.)

! RATE OF CHANGE

RACCEH=+K7hc-K8*ACCEH+K5*ACACEH-Ki2c*ABH*ACCEH ! RATE OF CHANGE
CONC. OF ACHE
ACCEH=INTEG(RACCEH,ACTCEH)
ACTIVITYCEH=(ACCEH/ACTCEH)*100
! ACHE ACTIVITY
RDEGCEH=K8*ACCEH
DEGCEH=INTEG(RDEGCEH,0.)
RAGECEH=K6*ACACEH
AGECEH=INTEG(RAGECEH,0.)

! ACHE AGING RATE

RINHCEH=Ki2c*ABH*ACCEH
INHCEH=INTEG(RINHCEH,0.)

! ACHE BINDING RATE

RINHCEHM=(RINHCEH*VH*.0000000001)*MWW
!-----HEART CARBOXYL II-----!
RACACEHf=Ki2c*ABH*ACCEHf-K5*ACACEHf-K6*ACACEHf
CHEMICAL BOUND TO ACHE
ACACEHf=INTEG(RACACEHf,0.)

! RATE OF CHANGE

RACCEHf=+K7hd-K8*ACCEHf+K5*ACACEHf-Ki2c*ABH*ACCEHf !RATE OF CHANGE
CONC. OF ACHE
ACCEHf=INTEG(RACCEHf,ACTCEHf)
ACTIVITYCEHf=(ACCEHf/ACTCEHf)*100
! ACHE ACTIVITY
RDEGCEHf=K8*ACCEHf
DEGCEHf=INTEG(RDEGCEHf,0.)
RAGECEHf=K6*ACACEHf
AGECEHf=INTEG(RAGECEHf,0.)

! ACHE AGING RATE

RINHCEHf=Ki2c*ABH*ACCEHf
! ACHE BINDING RATE
INHCEHf=INTEG(RINHCEHf,0.)
RINHCEHFM=(RINHCEHF*VH*.0000000001)*MWW
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activitych=0.5*(activityceh+activitycehf)
!-----ARTERIAL BLOOD ACHE-----!
RACm=K7abl-K8*ACm+K5*ACAm+K5*ABACam-KI*ABm*ACm-k1*abm*acm+k2*abacmKI2*ABACm*ABm
ACm=INTEG(RACm,actm)
!ACv=ACTv-ACAv-ABACv-ABACAv+K7abl-DEGv
ACTIVITYm=((ACm+ABACm)/actm)*100
RABACAm=ki2*ABACm*abm-K5*ABACAm-K6*ABACAM
ABACAm=INTEG(RABACAm,0.)
ablood=rbcsb+plasmab

! EQ 2

! TOTAL ACHE ELLMAN ACTIVITY BLOOD

RACAm=Ki*ABm*ACm-K5*ACAm-K6*ACAM
ACAm=INTEG(RACAm,0.)

! EQ 1

RBm=Ki*ABm*ACm+ki2*ABACm*ABm
Bm=INTEG(RBm,0.)

! EQ 1

RABACm=K1*ABm*ACm-k2*ABACm-Ki2*ABACm*abm!+k5*abacam
ABACm=INTEG(RABACm,0.)

! EQ 2

RBCS2=ABACM*140000!!!!!????
rbcs=ACM*140000 ! ACHE ACTIVITY IN RBCS OVER TIME UNINHIBIT
rbcsbAM=(rbcs+RBCS2)/(ACTM*140000)!4521380000 ! ACHE ACTIVITY IN
RBCS ELLMAN
rbcsb=((rbcs+RBCS2)/(ACTM*140000))*100!4521380000! ACHE ACTIVITY IN
RBCS ELLMAN
RACmP=K7ablP-K8*ACmP+K5*ACAmP+K5*ABACamP-KI*ABm*ACmP-k1*abm*acmP+...
k2*abacmP-KI2*ABACmP*ABm
ACmP=INTEG(RACmP,actmP)
RACAmP=Ki*ABm*ACmP-K5*ACAmP-K6*ACAMP
! EQ 1
ACAmP=INTEG(RACAmP,0.)
RABACmP=K1*ABm*ACmP-k2*ABACmP-Ki2*ABACmP*abm+k5*abacamP
! EQ 2
ABACmP=INTEG(RABACmP,0.)
RABACAmP=ki2*ABACmP*abm-K5*ABACAmP-K6*ABACAMP
! EQ 2
ABACAmP=INTEG(RABACAmP,0.)
RBCS2P=ABACMP*4800000!140000!!!!!????
rbcsP=ACMP*4800000!140000 ! ACHE ACTIVITY IN RBCS OVER TIME
UNINHIBIT rbcsbAMP=(rbcsP+RBCS2P)/(ACTMP*4800000)!4521380000 ! ACHE
ACTIVITY IN RBCS ELLMAN
rbcsbP=((rbcsP+RBCS2P)/(ACTMP*4800000))*100!4521380000 ! ACHE
ACTIVITY IN RBCS ELLMAN
RDEGm=K8*ACm
DEGm=INTEG(RDEGm,0.)
RAGEm=K6*ACAm
AGEm=INTEG(RAGEm,0.)

! ACHE AGING RATE
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RINHm=KI*ABm*ACm+KI2*ABm*ABACm
INHm=INTEG(RINHm,0.)

! ACHE BINDING RATE

RINHMM=(RINHM*VA*.0000000001)*MWW
!-----ARTERIAL BLOOD BUCHE-----!
RACABUM=Ki2b*ABM*ACBUM-K5*ACABUM-K6*ACABUM
CHEMICAL BOUND TO ACHE
ACABUM=INTEG(RACABUM,0.)

! RATE OF CHANGE

RACBUM=+K7bbl-K8*ACBUM+K5*ACABUM-Ki2b*ABM*ACBUM ! RATE OF CHANGE
CONC. OF ACHE
ACBUM=INTEG(RACBUM,ACTBUM)
ACTIVITYBUM=(ACBUM/ACTBUM)*100

! BUCHE PLASMA ACTIVITY

PLASMABU=ACBUM *2400000!ACTIVITYBUM*40000
PLASMABUT=ACTBUM *2400000!ACTIVITYBUM*40000
PLASMABUC=PLASMABU/PLASMABUT!*100 ! PLASMA BUCH/TOTAL PLASMA
ACTIVITY 0 TIME
BUCHE=(PLASMABU/PLASMABUC)*100
CHE=PLASMABUC+ABLOOD
ACHEP=rbcsP+RBCS2P
! ACHE IN PLASMA
PLASMAACT=ACTMP*4800000
PCHE=((PLASMABU+ACHEP)/(PLASMABUCHE+PLASMAACT))*100 ! TOTAL PLASMA
CHE(ACHE+BUCHE)
RDEGBUM=K8*ACBUM
DEGBUM=INTEG(RDEGBUM,0.)
RAGEBUM=K6*ACABUM
AGEBUM=INTEG(RAGEBUM,0.)

! ACHE AGING RATE

RINHBUM=Ki2b*ABM*ACBUM
! ACHE BINDING RATE
INHBUM=INTEG(RINHBUM,0.)
RINHBUMM=(RINHBUM*VA*.0000000001)*MWW
RSYNBUM=K7*(1-ACBUM/ACTBUM)
! ACHE SYNTHESIS RATE
SYNBUM=INTEG(RSYNBUM,0.)
!-----ARTERIAL BLOOD CARBOXYL-----!
RACACEM=Ki2c*ABM*ACCEM-K5*ACACEM-K6*ACACEM
CHEMICAL BOUND TO ACHE
ACACEM=INTEG(RACACEM,0.)

! RATE OF CHANGE

RACCEM=+K7blc-K8*ACCEM+K5*ACACEM-Ki2c*ABM*ACCEM ! RATE OF CHANGE
CONC. OF ACHE
ACCEM=INTEG(RACCEM,ACTCEM)
ACTIVITYCEM=(ACCEM/ACTCEM)*100
! ACHE ACTIVITY
RDEGCEM=K8*ACCEM
DEGCEM=INTEG(RDEGCEM,0.)
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RAGECEM=K6*ACACEM
AGECEM=INTEG(RAGECEM,0.)

! ACHE AGING RATE

RINHCEM=Ki2c*ABM*ACCEM
! ACHE BINDING RATE
INHCEM=INTEG(RINHCEM,0.)
RINHCEMM=(RINHCEM*VA*.0000000001)*MWW
!-----ARTERIAL BLOOD CARBOXYL-----!
RACACEMf=Ki2c*ABM*ACCEMf-K5*ACACEMf-K6*ACACEMf ! RATE OF CHANGE
CHEMICAL BOUND TO ACHE
ACACEMf=INTEG(RACACEMf,0.)
RACCEMf=+K7bld-K8*ACCEMf+K5*ACACEMf-Ki2c*ABM*ACCEMf ! RATE OF
CHANGE CONC. OF ACHE
ACCEMf=INTEG(RACCEMf,ACTCEMf)
ACTIVITYCEMf=(ACCEMf/ACTCEMf)*100
! ACHE ACTIVITY
RDEGCEMf=K8*ACCEMf
DEGCEMf=INTEG(RDEGCEMf,0.)
RAGECEMf=K6*ACACEMf
AGECEMf=INTEG(RAGECEMf,0.)

! ACHE AGING RATE

RINHCEMf=Ki2c*ABM*ACCEMf
INHCEMf=INTEG(RINHCEMf,0.)

! ACHE BINDING RATE

RINHCEMFM=(RINHCEMF*VA*.0000000001)*MWW
activitycm=0.5*(activitycem+activitycemf)
!-----VENOUS BLOOD ACHE-----!
RACv=K7abl-K8*ACv+K5*ACAv+K5*ABACav-KI*ABv*ACv-k1*abv*acv+k2*abacvKI2*ABACv*ABv
ACv=INTEG(RACv,actv)
!ACv=ACTv-ACAv-ABACv-ABACAv+K7abl-DEGv
ACTIVITYv=((ACv+ABACv)/actv)*100
RACAv=Ki*ABv*ACv-K5*ACAv-K6*ACAV
ACAv=INTEG(RACAv,0.)
RBv=Ki*ABv*ACv+ki2*ABACv*ABv
Bv=INTEG(RBv,0.)

! EQ 1
! EQ 1

RABACv=K1*ABv*ACv-k2*ABACv-Ki2*ABACv*abv!+k5*abacav
ABACv=INTEG(RABACv,0.)

! EQ 2

RABACAv=ki2*ABACv*abv-K5*ABACAv-K6*ABACAV
ABACAv=INTEG(RABACAv,0.)

! EQ 2

RDEGv=K8*ACv
DEGv=INTEG(RDEGv,0.)
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RAGEv=K6*ACAv
AGEv=INTEG(RAGEv,0.)

! ACHE AGING RATE

RINHv=KI*ABv*ACv+KI2*ABv*ABACv
INHv=INTEG(RINHv,0.)

! ACHE BINDING RATE

RINHVM=(RINHV*VV*.0000000001)*MWW
!-----VENOUS BLOOD BUCHE-----!
RACABUV=Ki2b*ABV*ACBUV-K5*ACABUV-K6*ACABUV ! RATE OF CHANGE CHEMICAL
BOUND TO ACHE
ACABUV=INTEG(RACABUV,0.)
RACBUV=+K7bblv-K8*ACBUV+K5*ACABUV-Ki2b*ABV*ACBUV ! RATE OF CHANGE
CONC. OF ACHE
ACBUV=INTEG(RACBUV,ACTBUV)
ACTIVITYBUV=(ACBUV/ACTBUV)*100
! ACHE ACTIVITY
RDEGBUV=K8*ACBUV
DEGBUV=INTEG(RDEGBUV,0.)
RAGEBUV=K6*ACABUV
AGEBUV=INTEG(RAGEBUV,0.)

! ACHE AGING RATE

RINHBUV=Ki2b*ABV*ACBUV
! ACHE BINDING RATE
INHBUV=INTEG(RINHBUV,0.)
RINHBUVM=(RINHBUV*VV*.0000000001)*MWW
!-----VENOUS BLOOD CARBOXYLESTERASE-----!
RACACEV=Ki2c*ABV*ACCEV-K5*ACACEV-K6*ACACEV ! RATE OF CHANGE CHEMICAL
BOUND TO ACHE
ACACEV=INTEG(RACACEV,0.)
RACCEV=+K7blc-K8*ACCEV+K5*ACACEV-Ki2c*ABV*ACCEV ! RATE OF CHANGE
CONC. OF ACHE
ACCEV=INTEG(RACCEV,ACTCEV)
ACTIVITYCEV=(ACCEV/ACTCEV)*100
! ACHE ACTIVITY
RDEGCEV=K8*ACCEV
DEGCEV=INTEG(RDEGCEV,0.)
RAGECEV=K6*ACACEV
AGECEV=INTEG(RAGECEV,0.)

! ACHE AGING RATE

RINHCEV=Ki2c*ABV*ACCEV
INHCEV=INTEG(RINHCEV,0.)

! ACHE BINDING RATE

RINHCEVM=(RINHCEV*VV*.0000000001)*MWW
SYNCEV=INTEG(RSYNCEV,0.)
!-----VENOUS BLOOD CARBOXYLESTERASE-----!
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! ACHE SYNTHESIS RATE

RACACEVf=Ki2c*ABV*ACCEVf-K5*ACACEVf-K6*ACACEVf ! RATE OF CHANGE
CHEMICAL BOUND TO ACHE
ACACEVf=INTEG(RACACEVf,0.)
RACCEVf=+K7bld-K8*ACCEVf+K5*ACACEVf-Ki2c*ABV*ACCEVf ! RATE OF CHANGE
CONC. OF ACHE
ACCEVf=INTEG(RACCEVf,ACTCEVf)
ACTIVITYCEVf=(ACCEVf/ACTCEVf)*100
! ACHE ACTIVITY
RDEGCEVf=K8*ACCEVf
DEGCEVf=INTEG(RDEGCEVf,0.)
RAGECEVf=K6*ACACEVf
AGECEVf=INTEG(RAGECEVf,0.)

! ACHE AGING RATE

RINHCEVf=Ki2c*ABV*ACCEVf
INHCEVf=INTEG(RINHCEVf,0.)

! ACHE BINDING RATE

RINHCEVFM=(RINHCEVF*VV*.0000000001)*MWW

! ACHE SYNTHESIS RATE

SYNCEVf=INTEG(RSYNCEVf,0.)
activitycv=0.5*(activitycev+activitycevf)
!-----OP PARENT MASS BALANCE-----!
TMASS=AF+AL+AS+AR+AM1+AM2+ABR+MR+ASK+AH+AV+AD
! TOTAL DOSE (MG)
DOSEX=AO+IVR*TINF
! NET AMOUNT ABSORBED (MG)
!-----OP OXON MASS BALANCE-----!
TMASSS=AFF+ALL+ASS+ARR+ABRR+ASKK+AM4+AM3+AMM+AHH+ADD! TOTAL DOSE
(MG)
DOSEXX=AOO+IVR*TINF
! NET AMOUNT ABSORBED (MG)
END
! END OF DERIVATIVE
'-------------------------------------------------------------------'
'--------------------------------------------------------------------'
TERMINAL
CALL LOGD(.TRUE.)
QLC=QLC+PDL
IF(QLC.LE.PMX) GO TO L1
END
END

! END OF PROGRAM
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